WO2021213759A1 - Particles for therapeutic purposes - Google Patents
Particles for therapeutic purposes Download PDFInfo
- Publication number
- WO2021213759A1 WO2021213759A1 PCT/EP2021/057372 EP2021057372W WO2021213759A1 WO 2021213759 A1 WO2021213759 A1 WO 2021213759A1 EP 2021057372 W EP2021057372 W EP 2021057372W WO 2021213759 A1 WO2021213759 A1 WO 2021213759A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- particles
- acupoint
- subject
- acupuncture
- typically
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims abstract description 342
- 230000001225 therapeutic effect Effects 0.000 title claims description 17
- 238000001467 acupuncture Methods 0.000 claims abstract description 102
- 239000000463 material Substances 0.000 claims abstract description 72
- 239000000203 mixture Substances 0.000 claims abstract description 45
- 230000001537 neural effect Effects 0.000 claims abstract description 40
- 210000004027 cell Anatomy 0.000 claims abstract description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 39
- 230000000694 effects Effects 0.000 claims abstract description 31
- 201000010099 disease Diseases 0.000 claims abstract description 27
- 108091008708 free nerve endings Proteins 0.000 claims abstract description 13
- 210000002265 sensory receptor cell Anatomy 0.000 claims abstract description 13
- 108091008691 sensory receptors Proteins 0.000 claims abstract description 13
- 102000027509 sensory receptors Human genes 0.000 claims abstract description 13
- 210000004126 nerve fiber Anatomy 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims description 35
- 210000003491 skin Anatomy 0.000 claims description 33
- 239000007788 liquid Substances 0.000 claims description 17
- 238000010438 heat treatment Methods 0.000 claims description 16
- -1 BL14 Proteins 0.000 claims description 14
- 210000002540 macrophage Anatomy 0.000 claims description 11
- 210000000412 mechanoreceptor Anatomy 0.000 claims description 9
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 9
- 101000592939 Bacillus subtilis (strain 168) 50S ribosomal protein L24 Proteins 0.000 claims description 8
- 230000007704 transition Effects 0.000 claims description 8
- 101001101476 Bacillus subtilis (strain 168) 50S ribosomal protein L21 Proteins 0.000 claims description 7
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 7
- 210000004698 lymphocyte Anatomy 0.000 claims description 7
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 6
- 101001093025 Geobacillus stearothermophilus 50S ribosomal protein L7/L12 Proteins 0.000 claims description 5
- 210000001789 adipocyte Anatomy 0.000 claims description 5
- 210000001772 blood platelet Anatomy 0.000 claims description 5
- 210000000716 merkel cell Anatomy 0.000 claims description 5
- 210000003607 pacinian corpuscle Anatomy 0.000 claims description 5
- 101000575029 Bacillus subtilis (strain 168) 50S ribosomal protein L11 Proteins 0.000 claims description 4
- 101000848201 Bos taurus Fibronectin type 3 and ankyrin repeat domains protein 1 Proteins 0.000 claims description 4
- 102100035793 CD83 antigen Human genes 0.000 claims description 4
- 101001070329 Geobacillus stearothermophilus 50S ribosomal protein L18 Proteins 0.000 claims description 4
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 4
- 210000002950 fibroblast Anatomy 0.000 claims description 4
- 210000003630 histaminocyte Anatomy 0.000 claims description 4
- 210000002510 keratinocyte Anatomy 0.000 claims description 4
- 210000001821 langerhans cell Anatomy 0.000 claims description 4
- 210000002752 melanocyte Anatomy 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 101710190981 50S ribosomal protein L6 Proteins 0.000 claims description 3
- 101001105315 Bacillus subtilis (strain 168) 50S ribosomal protein L17 Proteins 0.000 claims description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 3
- 238000011282 treatment Methods 0.000 description 41
- 230000000638 stimulation Effects 0.000 description 22
- 239000011248 coating agent Substances 0.000 description 20
- 230000011514 reflex Effects 0.000 description 18
- 239000002609 medium Substances 0.000 description 17
- 210000001186 vagus nerve Anatomy 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 15
- 210000005036 nerve Anatomy 0.000 description 14
- 230000002757 inflammatory effect Effects 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 230000007383 nerve stimulation Effects 0.000 description 13
- 230000004913 activation Effects 0.000 description 12
- 230000005855 radiation Effects 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- 210000002615 epidermis Anatomy 0.000 description 11
- 230000004054 inflammatory process Effects 0.000 description 11
- 206010061218 Inflammation Diseases 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000004936 stimulating effect Effects 0.000 description 10
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 206010040047 Sepsis Diseases 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 208000011231 Crohn disease Diseases 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 238000002296 dynamic light scattering Methods 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000002105 nanoparticle Substances 0.000 description 6
- 230000001272 neurogenic effect Effects 0.000 description 6
- 210000000578 peripheral nerve Anatomy 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 101100275990 Drosophila melanogaster Naus gene Proteins 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 5
- 229960004373 acetylcholine Drugs 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 210000004207 dermis Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 210000004761 scalp Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000002123 temporal effect Effects 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 208000024780 Urticaria Diseases 0.000 description 4
- 230000036982 action potential Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 4
- 238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 230000015788 innate immune response Effects 0.000 description 4
- 230000009456 molecular mechanism Effects 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- 201000008482 osteoarthritis Diseases 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 210000001428 peripheral nervous system Anatomy 0.000 description 4
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 230000003393 splenic effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 230000001960 triggered effect Effects 0.000 description 4
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- PZNSFCLAULLKQX-UHFFFAOYSA-N Boron nitride Chemical compound N#B PZNSFCLAULLKQX-UHFFFAOYSA-N 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 102400000096 Substance P Human genes 0.000 description 3
- 101800003906 Substance P Proteins 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000001800 adrenalinergic effect Effects 0.000 description 3
- 238000012382 advanced drug delivery Methods 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000004700 cellular uptake Effects 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 230000000536 complexating effect Effects 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 230000010189 intracellular transport Effects 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 238000002610 neuroimaging Methods 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000007441 retrograde transport Effects 0.000 description 3
- 210000003497 sciatic nerve Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 208000037911 visceral disease Diseases 0.000 description 3
- 206010000228 Abortion infected Diseases 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- 206010001889 Alveolitis Diseases 0.000 description 2
- 208000004881 Amebiasis Diseases 0.000 description 2
- 206010001980 Amoebiasis Diseases 0.000 description 2
- 206010002199 Anaphylactic shock Diseases 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 206010003011 Appendicitis Diseases 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000031729 Bacteremia Diseases 0.000 description 2
- 208000027496 Behcet disease Diseases 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 2
- 206010006448 Bronchiolitis Diseases 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 2
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 206010007134 Candida infections Diseases 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 206010008088 Cerebral artery embolism Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 206010009895 Colitis ischaemic Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 208000001490 Dengue Diseases 0.000 description 2
- 206010012310 Dengue fever Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 208000009366 Echinococcosis Diseases 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 208000037487 Endotoxemia Diseases 0.000 description 2
- 206010014824 Endotoxic shock Diseases 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- 208000000289 Esophageal Achalasia Diseases 0.000 description 2
- 206010016228 Fasciitis Diseases 0.000 description 2
- 201000006353 Filariasis Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101000760620 Homo sapiens Cell adhesion molecule 1 Proteins 0.000 description 2
- 206010020741 Hyperpyrexia Diseases 0.000 description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 2
- 206010021263 IgA nephropathy Diseases 0.000 description 2
- 208000024781 Immune Complex disease Diseases 0.000 description 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 206010029240 Neuritis Diseases 0.000 description 2
- 206010030136 Oesophageal achalasia Diseases 0.000 description 2
- 208000010191 Osteitis Deformans Diseases 0.000 description 2
- 206010031252 Osteomyelitis Diseases 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 208000027868 Paget disease Diseases 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010035742 Pneumonitis Diseases 0.000 description 2
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 2
- 206010037128 Pseudomembranous colitis Diseases 0.000 description 2
- 208000033464 Reiter syndrome Diseases 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 2
- 208000002359 Septic Abortion Diseases 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 206010046914 Vaginal infection Diseases 0.000 description 2
- 201000008100 Vaginitis Diseases 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- 208000027207 Whipple disease Diseases 0.000 description 2
- 201000000621 achalasia Diseases 0.000 description 2
- 230000004721 adaptive immunity Effects 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 206010003230 arteritis Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 238000013528 artificial neural network Methods 0.000 description 2
- 230000003376 axonal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 201000003984 candidiasis Diseases 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000003167 cholangitis Diseases 0.000 description 2
- 201000001352 cholecystitis Diseases 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 208000025729 dengue disease Diseases 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 208000007784 diverticulitis Diseases 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 206010014665 endocarditis Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 208000003401 eosinophilic granuloma Diseases 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 208000001606 epiglottitis Diseases 0.000 description 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 208000010710 hepatitis C virus infection Diseases 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 230000005661 hydrophobic surface Effects 0.000 description 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 2
- 208000024326 hypersensitivity reaction type III disease Diseases 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 239000010954 inorganic particle Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 201000010849 intracranial embolism Diseases 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 201000008222 ischemic colitis Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 208000027202 mammary Paget disease Diseases 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 108091008704 mechanoreceptors Proteins 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000008035 nerve activity Effects 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 230000004007 neuromodulation Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 208000011906 peptic ulcer disease Diseases 0.000 description 2
- 208000008494 pericarditis Diseases 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 206010034674 peritonitis Diseases 0.000 description 2
- 238000000554 physical therapy Methods 0.000 description 2
- 208000008423 pleurisy Diseases 0.000 description 2
- 201000006292 polyarteritis nodosa Diseases 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000012877 positron emission topography Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 201000007094 prostatitis Diseases 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000002574 reactive arthritis Diseases 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000030925 respiratory syncytial virus infectious disease Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 210000001044 sensory neuron Anatomy 0.000 description 2
- 208000013223 septicemia Diseases 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000000106 sweat gland Anatomy 0.000 description 2
- 201000004595 synovitis Diseases 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 201000005060 thrombophlebitis Diseases 0.000 description 2
- 206010043778 thyroiditis Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000003901 trigeminal nerve Anatomy 0.000 description 2
- 208000025883 type III hypersensitivity disease Diseases 0.000 description 2
- 208000000143 urethritis Diseases 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 101710135913 50S ribosomal protein L27 Proteins 0.000 description 1
- 101710135934 50S ribosomal protein L36 Proteins 0.000 description 1
- 101710190962 50S ribosomal protein L9 Proteins 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 1
- 101100365087 Arabidopsis thaliana SCRA gene Proteins 0.000 description 1
- 108700019909 BL 19 Proteins 0.000 description 1
- 229910052582 BN Inorganic materials 0.000 description 1
- 101000682328 Bacillus subtilis (strain 168) 50S ribosomal protein L18 Proteins 0.000 description 1
- 101000676341 Bacillus subtilis (strain 168) 50S ribosomal protein L27 Proteins 0.000 description 1
- 101001113309 Bacillus subtilis (strain 168) 50S ribosomal protein L30 Proteins 0.000 description 1
- 101000712130 Bacillus subtilis (strain 168) 50S ribosomal protein L7/L12 Proteins 0.000 description 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 101000869912 Cerastes vipera Disintegrin CV-11-alpha Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 1
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 1
- 102100035167 Coiled-coil domain-containing protein 54 Human genes 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 102100035353 Cyclin-dependent kinase 2-associated protein 1 Human genes 0.000 description 1
- 229930182843 D-Lactic acid Natural products 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 229910017356 Fe2C Inorganic materials 0.000 description 1
- 101000660293 Geobacillus stearothermophilus 50S ribosomal protein L32 Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108700010013 HMGB1 Proteins 0.000 description 1
- 101150021904 HMGB1 gene Proteins 0.000 description 1
- 102100037907 High mobility group protein B1 Human genes 0.000 description 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 1
- 101000737052 Homo sapiens Coiled-coil domain-containing protein 54 Proteins 0.000 description 1
- 101000737813 Homo sapiens Cyclin-dependent kinase 2-associated protein 1 Proteins 0.000 description 1
- 101000911772 Homo sapiens Hsc70-interacting protein Proteins 0.000 description 1
- 101001046633 Homo sapiens Junctional adhesion molecule A Proteins 0.000 description 1
- 101001139126 Homo sapiens Krueppel-like factor 6 Proteins 0.000 description 1
- 101001005708 Homo sapiens MARVEL domain-containing protein 1 Proteins 0.000 description 1
- 101001059990 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 2 Proteins 0.000 description 1
- 101001106523 Homo sapiens Regulator of G-protein signaling 1 Proteins 0.000 description 1
- 101000710013 Homo sapiens Reversion-inducing cysteine-rich protein with Kazal motifs Proteins 0.000 description 1
- 101000824971 Homo sapiens Sperm surface protein Sp17 Proteins 0.000 description 1
- 101000661816 Homo sapiens Suppression of tumorigenicity 18 protein Proteins 0.000 description 1
- 101000661807 Homo sapiens Suppressor of tumorigenicity 14 protein Proteins 0.000 description 1
- 101000585359 Homo sapiens Suppressor of tumorigenicity 20 protein Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108010034143 Inflammasomes Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102100022304 Junctional adhesion molecule A Human genes 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- 102100025069 MARVEL domain-containing protein 1 Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 102100028192 Mitogen-activated protein kinase kinase kinase kinase 2 Human genes 0.000 description 1
- 101001067830 Mus musculus Peptidyl-prolyl cis-trans isomerase A Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100021269 Regulator of G-protein signaling 1 Human genes 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 102100025639 Sortilin-related receptor Human genes 0.000 description 1
- 101710126735 Sortilin-related receptor Proteins 0.000 description 1
- 102100029860 Suppressor of tumorigenicity 20 protein Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 101100438139 Vulpes vulpes CABYR gene Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 210000001943 adrenal medulla Anatomy 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000005904 anticancer immunity Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- JRPBQTZRNDNNOP-UHFFFAOYSA-N barium titanate Chemical compound [Ba+2].[Ba+2].[O-][Ti]([O-])([O-])[O-] JRPBQTZRNDNNOP-UHFFFAOYSA-N 0.000 description 1
- 229910002113 barium titanate Inorganic materials 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical class C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000000768 catecholaminergic effect Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000027448 caveolin-mediated endocytosis Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000006896 clathrin and caveolin independent endocytosis Effects 0.000 description 1
- 230000006395 clathrin-mediated endocytosis Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 238000000604 cryogenic transmission electron microscopy Methods 0.000 description 1
- 108091008710 cutaneous receptors Proteins 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 229940022769 d- lactic acid Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 102000013035 dynein heavy chain Human genes 0.000 description 1
- 108060002430 dynein heavy chain Proteins 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 210000002310 elbow joint Anatomy 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 231100000284 endotoxic Toxicity 0.000 description 1
- 230000002346 endotoxic effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 230000005293 ferrimagnetic effect Effects 0.000 description 1
- 238000001825 field-flow fractionation Methods 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000000020 growth cone Anatomy 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 108090000237 interleukin-24 Proteins 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000003120 macrolide antibiotic agent Chemical class 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 210000000236 metacarpal bone Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000034778 micropinocytosis Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000004699 muscle spindle Anatomy 0.000 description 1
- 108091008709 muscle spindles Proteins 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 210000000118 neural pathway Anatomy 0.000 description 1
- 230000010004 neural pathway Effects 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 230000008906 neuronal response Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 230000002669 organ and tissue protective effect Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 102000007863 pattern recognition receptors Human genes 0.000 description 1
- 108010089193 pattern recognition receptors Proteins 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000003238 somatosensory effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000000498 stratum granulosum Anatomy 0.000 description 1
- 210000000439 stratum lucidum Anatomy 0.000 description 1
- 210000000437 stratum spinosum Anatomy 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000000331 sympathetic ganglia Anatomy 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000001931 thermography Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000001515 vagal effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 210000003857 wrist joint Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/36017—External stimulators, e.g. with patch electrodes with leads or electrodes penetrating the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H39/00—Devices for locating or stimulating specific reflex points of the body for physical therapy, e.g. acupuncture
- A61H39/002—Using electric currents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0504—Subcutaneous electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
- A61N1/403—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia
- A61N1/406—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia using implantable thermoseeds or injected particles for localized hyperthermia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
- A61N2005/066—Radiation therapy using light characterised by the wavelength of light used infrared far infrared
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0619—Acupuncture
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to particles and compositions comprising such particles for use for treating a subject suffering of a disease via an acupuncture effect when particles stably interact with biological cells, free nerve endings, end-organs, nerve fibers and/or sarcous sensory receptors of at least one acupoint or Neural Acupuncture Unit (NAU) of the subject.
- the particles used in the context of the present invention are preferably below 100 pm and are preferably prepared from a material selected from a piezoelectric material, a pyroelectric material and a far-infrared radiation-emitting material.
- the activation of macrophages, dendritic cells, neutrophils, natural killers and other immune cells is pivotal in inflammation to restore tissue homeostasis.
- Macrophages and dendritic cells function as antigen-presenting cells and bridge innate and adaptive immune response.
- T and B lymphocytes Upon antigen exposure, T and B lymphocytes undergo cell division and maturation and play key roles in antigen- specific adaptive immunity. The release of cytokines, chemokines and other inflammatory mediators amplifies the inflammatory process.
- pattern-recognition receptors and cytokine receptors are expressed on neurons.
- receptors for acetylcholine and other neurotransmitters are expressed on macrophages, dendritic cells and other immune cells.
- Peripheral immune cells also synthesize and release acetylcholine, catecholamines and other molecules classically identified as neurotransmitters [Menna R. Clatworthy et al. The nervous spleen. Immunology and Cell Biology, 2008, 86, 1-2]
- a neural reflex i.e., a neuronal circuit operating reflexively
- a neural reflex is defined by three components: first, a sensory receptor capable of responding to a change in the environment; second, a sensory afferent arc that transmits action potentials into the nervous system; and third, a motor efferent arc that sends action potentials from the nervous system back to the periphery to modulate environment.
- Known neural reflex circuitry involved in immunity are the inflammatory reflex, the vagus nerve-adrenal reflex, the enteric-neural reflex, the neural reflex in cancer, the gateway reflex, the nociceptive reflex in the lung, the axon-axon reflex [S.S. Chavan et al. Essential Neuroscience in Immunology. The Journal of Immunology. 2017; 198:3389-3397; K.J. Tracey. Reflexes in Immunity. Cell 164, January 28, 2016; 343]
- One particularly well-characterized neuronal circuit regulating innate immunity is the inflammatory reflex, a neural reflex circuit of action potentials traveling in the sensory and motor vagus nerves that regulate cytokine production in the spleen.
- the efferent action potentials traveling down the vagus nerve culminate in the celiac ganglion, the site of origin of adrenergic splenic nerve.
- the splenic nerve is adrenergic, producing norepinephrine in the vicinity of lymphocytes in the spleen.
- a discreet subset of lymphocytes regulated by splenic nerve signal express choline acetyltransferase, the rate limiting enzyme in the biosynthesis of acetylcholine.
- Acetylcholine-induced signal transduction in monocytes and macrophages is mediated by a-7 nicotinic acetylcholine receptors which inhibit the nuclear translocation ofNF-kB, activate the JAK2/STAT3 pathway, stabilize mitochondrial membranes, and downregulate the activity of the inflammasome.
- vagus nerve-mediated signals within the spleen is the inhibition of cytokine release by the red pulp and marginal zone macrophages, which together account for 90% of the TNF and IF-1 produced during typically acute endotoxemia [Kevin J. Tracey. The inflammatory reflex. Nature, 2002. 420, 853-859; Valentin A. Pavlov etal. Neural regulation of immunity: molecular mechanisms and clinical translation. Nature Neuroscience. 2017, 20(2), 156-166; Sangeeta S. Chavan et al. Essential Neuroscience in Immunology. The Journal of Immunology. 2017, 198, 3389-3397; J.M. Huston et al. The inflammatory reflex and neural tourniquet: harnessing the healing power of the vagus nerve. Bioelectron. Med., 2018; 1(1); 29-38]
- the bioelectronic medicine that stimulate the peripheral nervous system has been used to treat injury and disease.
- the bioelectronic medicine utilize tools to interface with the nervous system to modulate and control the immune response and the physiological state of organs and systems.
- communication within the neural network occurs via electrical signals that travel rapidly and specifically along nerves. Upon reaching their intended cellular and molecular targets, these electrical signals cause the release of neurotransmitters.
- bioelectronic medicine harnesses endogenous pathways for therapeutic purposes.
- Invasive vagus nerve stimulation is currently approved for the treatment of medically refractory epilepsy and depression and clinical trials are ongoing for the treatment of sepsis and inflammatory disorders, including rheumatoid arthritis and Crohn’s disease. [D. Fox.
- transdermal nerve stimulation represents another alternative strategy which is minimally invasive for nerve stimulation.
- the percutaneous electrical nerve stimulation (PENS) is delivered by insertion of electrodes near the peripheral nerves which is to be stimulated.
- Wireless PENS has also been proposed.
- the Stimwave system used for pain relief, typically involves an implant which comprises a stimulator and a micro-receiver, an electronic device (i.e., Wearable Antenna Assembly: WAA) used to power the receiver, the implanted receiver and stimulator only accepting power and parameter settings from a specific WAA, personalized for each patient, and a programmer (Apple watch, Apple Touch, IPad programmer).
- WAA Wearable Antenna Assembly
- PENS represents a useful alternative for subjects who may not support transcutaneous electrical stimulation or when wanting to avoid skin resistance. PENS is sometimes assimilated to electroacupuncture when the stimulation is given at an acupoint.
- acupuncture including manual acupuncture, electroacupuncture, pressure acupuncture, laser acupuncture and heat acupuncture
- Clinical studies showed that acupuncture can improve post-operative recovery, osteoarthritis, migraine, joint pain, stroke, post-traumatic stress disorder and drug addiction
- Neuromodulation with acupuncture or electroacupuncture is endorsed by the WHO and NIH and it is used by millions of people to control pain, inflammation and to reestablish physiological homeostasis during illness.
- Vagus nerve stimulation via acupuncture has also been used to alter bowel function, gastric acidity and heart rate [K.J. Tracey. The Inflammatory Reflex. Nature, 2002; 420; 853-859]
- Activation of an anti inflammatory reflex involving the vagus nerve was described in endotoxemic rats using electroacupuncture at a point located at the junction of the first and the second metacarpal bones. In this reflex, somatosensory stimulation via unknown mechanism reaches the brain and triggers activation of muscarinic acetylcholine receptor-mediated signaling.
- Electroacupuncture at another acupuncture point causes stimulation of sciatic nerve activity in a voltage dependent manner. Signals arising in the sciatic nerve culminate on efferent vagus nerve signals. The efferent vagus nerves signals terminate on the release of dopamine in the adrenal medulla.
- Dopamine induced by sciatic nerve stimulation targets dopaminergic type 1 (Dl) receptors and suppresses systemic inflammation through D1 -receptor-mediated mechanism and results in improved survival of mice with cecal ligation and puncture-induced polymicrobial sepsis
- Dl dopaminergic type 1
- I Diseases symptoms or conditions for which acupuncture has been proved - through controlled trials - to be an effective treatment.
- treatment for depression including depressive neurosis and depression following stroke
- Rheumatoid arthritis are listed.
- 2_Diseases symptoms or conditions for which the therapeutic effect of acupuncture has been shown but for which further proof is needed.
- treatment for Diabetes mellitus, non-insulin- dependent, osteoarthritis and schizophrenia are listed.
- 3_Diseases symptoms or conditions for which there are only individual controlled trials reporting some therapeutic effects, but for which acupuncture is worth trying because treatment by conventional and other therapies is difficult.
- Pulmonary heart disease Chronic (CCS) and Irritable (ICS) Colon Syndrome are listed.
- the proposed nomenclature for the 48 extra points consists of a prefix “EX” denoting “extra point” followed by an alphabetical code indicating the region (HN for head and neck, CA for chest and abdomen, B for back, UE for upper extremity and LE for lower extremity).
- the World Health Organization has presented a methodology for locating acupuncture points on the surface of a human body, as well as the location of 361 acupunctures points (acupoints) [WHO Standard Acupuncture Point Locations in the Western Pacific Region, 2008] Three methods are described for locating acupuncture points: The anatomical landmark method, the proportional bone (skeletal) measurement method (using the B-cun as standard measuring unit) and the finger-cun measurement method (using the F-cun as standard measuring unit).
- Nerves, at the acupoints can be stimulated with different technique including pressure (acupressure), massage, heat (moxibustion for example), sound (sonopuncture) or electricity (electroacupuncture) .
- Acupoints are specific points of the human body that have demonstrated mechanical hypersensitivity and have high electrical conductance. Sensory nerve endings are distributed unevenly over the body and acupoints have a higher density of sensory nerve endings than surrounding areas.
- NAU Neural Acupuncture Unit
- acupoints associated with internal organs can be identified as neurogenic inflammatory spots occurring on the skin that are associated with visceral disorders.
- These cutaneous “neurogenic spots” function as therapeutic acupoints (i.e., electroacupuncture at neurogenic spots generates therapeutic effects like acupuncture effects), and are characterized by plasma extravasation and vasodilation in the postcapillary venules of the skin arising from release of calcitonin gene-related peptide (CGRP) and substance P (SP) from activated small diameter sensory afferents.
- CGRP calcitonin gene-related peptide
- SP substance P
- Acupoint reflects the status of a visceral organ, and visceral disorders can be treated by manipulating acupoints.
- Acupoints or NAUs for which a large portion of surrounding biological components is made of muscle fibers include among other Zusanli (ST36), Hegu (LI4) and Huantiao (GB30).
- Zusanli (ST36) or at the Hegu (LI4) acupoint are typically shown to modulate inflammatory responses in internal organs [H.-D. Lim el al. Anti-inflammatory effects of acupuncture stimulation via the vagus nerve. PLOS ONE, DOI: 10.1371/joumal.pone.0151882, 2016; V.A. Pavlov etal.
- Acupoints or NAUs for which a large portion of surrounding biological components is made of cutaneous receptors include acupoints located in the finger pads, palms, plantar area, and the surrounding lips such as Shaoshang (LU11) and Shuigou (GV26).
- Acupoints or NAUs for which a large portion of surrounding biological components is made of tendons organs, Ruffini corpuscles and Pacinian corpuscles include acupoints located around elbow, wrist, and ankle joints such as Chize (LU5), Daling (PC7), Dubi (ST35) and Jiexi (ST41).
- Neuroactive components of NAUs are non-neuronal tissues and biological cells as well as the various mediators capable of modulating NAU afferent signals via local biochemical reactions which are released by these tissues and cells.
- biophysical reactions of NAUs are triggered by the activation of mechanoreceptors.
- Multiple central neural pathways convey NAU afferent impulses.
- a distributed network of widespread brain regions that respond to acupuncture provides the neural substrate for broad therapeutic effects of acupuncture.
- Clinical studies have revealed that acupuncture treatment was capable of normalizing abnormal neuroimaging activity in patients with Alzheimer’s disease, major depressive disorder, etc..
- neuroimaging approaches such as functional magnetic resonance imaging (fMRI) and positron emission topography (PET) have been widely introduced into acupuncture research.
- fMRI functional magnetic resonance imaging
- PET positron emission topography
- Table 1 lists the main existing bioelectronic medical technologies used to treat diseases in relation with inflammation and infection.
- the invasiveness of each of the herein above described technologies, its spatial and temporal resolution, its safety risk as well as its ability to offer autonomy to the subject receiving the treatment (i.e. ability of the subject to receive treatment without impact on daily activities) are criteria evaluated/estimated as follows: ⁇ (high negative impact on one or more criteria), ⁇ (moderate negative impact on one or more criteria), ⁇ (no negative impact on criteria).
- the present invention provides a solution to this unmet need which advantageously satisfies all of the criteria listed above.
- the herein below described invention is moderately invasive (similar to acupuncture’s invasiveness) and safe, offers optimal spatial and temporal resolution, and allows the subject to manage the therapeutic treatment without the physical help of a practitioner, typically of an acupuncturist.
- Inventors herein describe particles for use for treating a subject suffering of a disease via an acupuncture effect when particles stably interact with biological cells, free nerve endings, end-organs, nerve fibers and/or sarcous sensory receptors (present in the biological medium) of at least one acupoint or NAU of the subject, and to a composition for use for treating a subject suffering of a disease, wherein the composition comprises particles and the therapeutic effect is obtained via an acupuncture effect when particles interact with biological cells, free nerve endings, end-organs, nerve fibers and/or sarcous sensory receptors (present in the biological medium) of at least one acupoint or NAU of the subject.
- Particles are preferably below 100 pm and are preferably prepared from a material selected from a piezoelectric material, a pyroelectric material and a far-infrared radiation-emitting material.
- the description further relates to a method for delivering acupuncture to a subject in need thereof.
- the method typically comprises a step of administering the particles, or a composition comprising the particles, to at least one acupoint or Neural Acupuncture Unit (NAU) of the subject, thereby triggering an acupuncture effect in the subject.
- NAU Neural Acupuncture Unit
- the method for treating a subject suffering of a disease via an acupuncture effect / for delivering acupuncture to a subject in need thereof typically comprises a step of administering the particles, or a composition comprising the particles, to at least one acupoint or Neural Acupuncture Unit (NAU) of the subject, and a step of stimulating said particles by a skin massage on the at least one acupoint or NAU, thereby triggering an acupuncture effect in the subject.
- NAU Neural Acupuncture Unit
- the method for treating a subject suffering of a disease via an acupuncture effect / for delivering acupuncture to a subject in need thereof typically comprises a step of administering the particles, or a composition comprising the particles, to at least one acupoint or Neural Acupuncture Unit (NAU) of the subject, and a step of stimulating said particles by heating the surface of the skin of the subject above the acupoint or NAU, thereby triggering an acupuncture effect in the subject.
- NAU Neural Acupuncture Unit
- the description also relates to a method for treating a subject in need thereof via an acupuncture effect.
- the method typically comprises a step of administering the particles, or a composition comprising the particles, to at least one acupoint or Neural Acupuncture Unit (NAU) of the subject, thereby treating the subject.
- NAU Neural Acupuncture Unit
- the method typically comprises a step of administering the particles, or a composition comprising the particles, to at least one acupoint or Neural Acupuncture Unit (NAU) of the subject, and a step of stimulating said particles by a skin massage on the at least one acupoint or NAU, thereby treating the subject.
- NAU Neural Acupuncture Unit
- the method typically comprises a step of administering the particles, or a composition comprising the particles, to at least one acupoint or Neural Acupuncture Unit (NAU) of the subject, and a step of stimulating said particles by heating the surface of the skin of the subject above the acupoint or NAU, thereby treating the subject.
- NAU Neural Acupuncture Unit
- Inventors herein describe particles for use for treating a subject suffering of a disease via an acupuncture effect when particles stably interact with biological cells, free nerve endings, end-organs, nerve fibers and/or sarcous sensory receptors (present in the biological medium) of at least one acupoint or Neural Acupuncture Unit (NAU) of the subject.
- Preferred therapeutic particles are below 100 pm, and are prepared from a material selected from a piezoelectric material, a pyroelectric material and a far-infrared radiation-emitting material.
- the present invention optimizes the efficacy of treatments involving peripheral nerve stimulation while minimizing the detrimental effects/risk compared to existing treatments using bioelectronic approaches. In addition, it facilitates patient’s autonomy.
- the material constituting the particles of the invention as well as their structure are key to obtain the desired therapeutic efficacy. Indeed, the particle’s efficacy directly depends on the specific intrinsic property of the material constituting the particle. A careful selection of the composition and structure (i.e., an amorphous structure, a semi-crystalline structure or a crystalline structure) of the particles therefore optimizes the temporal energy input signal transduction and/or the temporal energy input signal modulation.
- the particle of the invention can be a piezoelectric particle, typically a piezoelectric particle having a structure and/or composition capable of converting in vivo an external mechanical input signal into an internal electrical output signal.
- the particle When the particle is a piezoelectric particle, it typically consists of a quartz (S1O2) particle, a barium titanate (BaTiO,) particle, a AIN particle, a GaN particle, a ZnO particle, a boron nitride (BN) particle or a particle comprising or consisting in polyvinylidene fluoride polymer or a derivative thereof, polymeric L-lactic acid, polymeric D-lactic acid, DNA or M13 bacteriophage.
- a quartz (S1O2) particle a barium titanate (BaTiO,) particle
- a AIN particle a GaN particle
- ZnO particle a boron nitride (BN) particle
- BN boron nitride
- piezoelectric particles in contact with the peripheral nervous system on at least one acupoint and/or NAU, stimulate the peripheral nerves when activated by a skin massage on the acupoint or NAU.
- This stimulation of the nerve’s internal electrical signal is rendered possible by the intrinsic piezoelectric property of the particles selected for use in the context of the present invention which are “activated” when a skin massage is performed on the acupoint or NAU where the piezoelectric particles are located.
- the particle of the invention can be a pyroelectric particle.
- the particle is a pyroelectric particle, it is typically a UiTaCri particle or it is a particle comprising or consisting in PVDF polymer.
- These pyroelectric particles in contact with the peripheral nervous system on at least one acupoint and/or NAU, stimulate in vivo the peripheral nerves when activated.
- the activation is obtained by heating the surface of the skin of the subject above the acupoint or NAU where the pyroelectric particles are located.
- This stimulation of the nerve’s internal electrical signal is rendered possible by the intrinsic pyroelectric property of the particles selected for use in the context of the present invention which are “activated” when a step of heating the surface of the skin of the subject above the acupoint or NAU where the pyroelectric particles are located is performed.
- the particle of the invention can be a far-infrared radiation-emitting particle.
- the particle is a far-infrared radiation emitting particle, it is typically an inorganic particle, preferentially a metal oxide particle with an emissivity level of more than 50%, preferably more than 60%, more than 70%, more than 80%, or more than 90%, and emitting between 4 microns and 200 microns, preferably between 4 microns and 50 microns, or between 4 microns and 20 microns.
- the inorganic particle capable of emitting far-infrared radiation is typically an AI 2 O 3 particle, a Fe 2 C> 3 particle, a MgO particle, a ZrC particle or a Y 2 O 3 particle.
- These far-infrared radiation emitting particles in contact with the peripheral nervous system on at least one acupoint and/or NAU, stimulate/modulate in vivo the electrical signal. This signal is then conducted by said nerves up to the central nervous system (CNS). This stimulation/modulation of the nerve’s internal electrical signal is rendered possible by the intrinsic far-infrared radiation emitting property of the particles selected for use in the context of the present invention (i.e., an increase of the temperature at acupoint or NAU is obtained by converting radiation emitted by the particle into heat).
- Particles have been selected by inventor for their ability to stably interact with biological entities present on at least one acupoint and/or NAU and to efficiently stimulate the peripheral nerves.
- the expression “stably interacting” indicates that particles (i) do not move after injection/administration on at least one acupoint or NAU, i.e. at least, preferably more than 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90%, even more preferably more than 80% or 90%, of the injected dose of particles remain at the site of injection, the particles interacting with elements of the biological medium present on the at least one acupoint or NAU and/or with the biological cells, i.e.
- the particles By stably interacting with the biological entities present on at least one acupoint and/or NAU, the particles ensure a high spatial resolution for signal transmission.
- the biological cells of interest the particles are directly or indirectly stably interacting with at the site of injection typically comprise keratinocytes, melanocytes, Merkel cells, Langerhans cells, fibroblasts, mast cells, macrophages, lymphocytes, platelets and/or lipocytes.
- Particles also directly or indirectly stably interact with the other elements typically present in the biological medium of at least one acupoint or NAU, i.e., with free nerve endings, nerves fibers, sarcous sensory receptors and/or end-organs, the end-organs being typically Meissner corpuscles, Ruffini corpuscles, Pacinian corpuscles and/or longitudinal lanceolate endings.
- the two following particles’ features are to be properly selected: (i) the size of the particles and (ii) the composition of the particles’ core and/or of the particles’ surface coating.
- the particles’ size is typically below about 100 pm.
- a threshold limit of the particles’ size of about 200 nm has been observed regarding uptake and retrograde transport of particles following axonal delivery in cortical neuronal cells [Anna Uesniak el al. Rapid growth cone uptake and dynein-mediated axonal retrograde transport of negatively charged nanoparticles in neurons is dependent on size and cell type. Small, 2018, 1803758] Uptake and retrograde transport were observed for particles having a size up to 100 nm whereas they were hardly observed for particles having a size typically above about 200 nm.
- the size of the particles is preferably between about 200 nm and about 100 pm.
- the size of the particles is typically measured using well-known electron microscopic (EM) tools or light scattering tools.
- EM electron microscopic
- the size of the particles is typically measured using an electron microscopic technic, typically scanning electron microscopy.
- the longest dimension of the core of a particle (the core of the particle being the particle without any surface coating) measured in the electron microscopy image is reported.
- At least 100 particles of a population are measured in their longest dimension and the median size of the considered population of particles is calculated.
- the “size” of the particles designates the median size of the particles of a population comprising at least 100 particles.
- the size of the particles is typically measured using the Dynamic Light Scattering (DLS) technique.
- DLS Dynamic Light Scattering
- the size of the particle is typically measured when the particles are in aqueous suspension (i) at a pH between about 6.5 and about 7.5, (ii) at a particles’ concentration between 0.5 g/kg and 10 g/kg (weight/weight), the particles’ concentration being typically measured by dry extract (i.e.
- the suspension containing the particles is typically placed at a temperature between 100°C and 250°C for a duration period typically comprised between 15 minutes and overnight) or by ICP-MS or by ICP-OES and (iii) at an ionic strength presenting an electrical conductivity typically comprised between about 0.01 pS/cm and about 2000 pS/cm at a temperature between about 15°C and about 25°C.
- the size of the particles corresponds to the size of the particles given in intensity.
- the electron microscopy technique typically the transmission electron microscopy (TEM) or Cryo-TEM can be used to measure the size of the particles at the nanoscale.
- EM electron microscopy technique
- TEM transmission electron microscopy
- Cryo-TEM Cryo-TEM
- the longest dimension of a particle measured in the electron microscopy image is reported.
- At least 100 particles are measured in their longest dimension and a median size of the particles of the population comprising at least 100 particles is calculated.
- the “size” of the particles designates the median size of the particles of a population comprising at least 100 particles.
- the particle size is polydisperse (i.e., the polydispersity index of the suspension of particle is found typically above 0.2 when measured by DLS)
- a fractionation technique can be used to separate the populations of particles in different monodisperse particles’ size populations.
- a field flow fractionation tool can be used to reach this goal.
- the size of the particles in each population/fraction is determined as described herein-above using DLS or EM tools.
- the quantity of particles is estimated. This estimation can typically be done by quantification of at least one element constituting the particle.
- the “size” of the particles represents in this context the average weight of the sizes of the particles obtained in each population of particles or fraction thereof.
- the shape of particle is not critical for the invention.
- the particle can have an “inhomogeneous shape”.
- the expression “inhomogeneous shape” designates particle the sizes of which have been measured in the 3 dimension (x, y, z) and present one or two dimensions larger than the other(s), typically one or two dimensions more than about three times larger than the other(s).
- a particle with a homogeneous shape is preferred.
- the expression “homogeneous shape” designates particle the sizes of which have been measured in the 3 dimension (x, y, z) and present a ratio which does not exceed a factor 3 between each dimension (i.e., x/y ⁇ 3, y/z ⁇ 3 and z/x ⁇ 3).
- the particles Whatever the surface of the particles, they will most certainly end up within biological cells when their size is below about 20 pm or 10 pm. On the contrary, whatever the surface of the particles, they will be localized preferentially outside biological cells, typically in the biological medium surrounding the cells when their size is typically above about 10 pm or 20 pm. Indeed, when the size of the particles is typically below 20 pm, the particles can enter cells by different mechanisms: through endocytosis-dependent pathways or direct cytoplasmic delivery [Nathan D. Donahue, et al. Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine.
- Endocytic -dependent pathways encompass five mechanistically distinct classes: (a) clathrin-dependent endocytosis for particles’ size typically between about 100 nm and about 500 nm; (b) caveolin-dependent endocytosis for particles’ size typically between about 50 nm and about 100 nm; (c) clathrin- and caveolin-independent endocytosis; (d) phagocytosis, typically used by immune cells, including macrophages, dendritic cells, neutrophils, and B lymphocytes, for particles’ size typically up to about 20 pm, preferentially up to about 10 pm; and (e) micropinocytosis for particles’ size typically between about 0.5 pm and about 1.5 pm [Nathan D. Donahue, et al. Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine. Advanced Drug Delivery Reviews 143 (2019) 68-96]
- direct injection of particles into the cytoplasm of biological cells present on at least one acupoint may be performed in the context of the present invention, the biological cells being preferably selected from keratinocytes, melanocytes, Merkel cells, Langerhans cells, fibroblasts, mast cells, macrophages, lymphocytes, platelets, lipocytes and any combination thereof.
- the biological cells being preferably selected from keratinocytes, melanocytes, Merkel cells, Langerhans cells, fibroblasts, mast cells, macrophages, lymphocytes, platelets, lipocytes and any combination thereof.
- technics may be used via biochemical or physical means, including electroporation or microinjection [Nathan D. Donahue, et al. Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine. Advanced Drug Delivery Reviews 143 (2019) 68-96]
- the size of the particles below about 100 pm will ensure relevant (i.e., stable) interaction between the particles of the invention and the biological medium where the particles have been injected.
- a direct interaction of the particle with the cell is possible, and the particle can even operate from within the cell.
- the particles having the same size-scale as a cell they are capable of significantly enhancing smooth interactions both with the biological cells and with the biological medium compared to current implants (typically needles used for electroacupuncture have a much larger diameter than the size of a cell).
- composition of the particles and/or of the particles surface coating agent
- a surface coating is preferably applied using a surface coating agent.
- This surface coating is preferably an inorganic surface coating limiting, ideally preventing, any potential degradation of the organic surface coating agent (such as bond breaking) upon time, ex-vivo (i.e., upon storage of the particles prior use) or in vivo (i.e., upon injection of the particles in vivo).
- the surface coating agent should ideally not contain carbon-carbon bonds or any bonds susceptible of being broken ex vivo or in vivo (typically due to oxidation phenomenon).
- precaution regarding sterilization and storage of the particles are to be taken to prevent potential degradation of the surface coating agent, typically due to oxidation reactions.
- the surface coating agent should be selected so that potential residues or moieties typically resulting from oxidation reactions and/or bond breaking of the surface coating agent do not triggered in vivo toxicity.
- this surface coating agent should not desorb from the particles’ core. Therefore, it is key to consider coating agent able to establish strong bonds/links with the surface of the particles, typically able to establish complexing or covalent bonds. Typical covalent bonds are found between silane-based compounds (i.e., coating agents) and the surface of oxide particles.
- bonds considered as exhibiting a strength intermediate between the strength exhibited by covalent bonds and that exhibited by complexing bonds are found between phosphate-based or phosphonate-based compounds (i.e., coating agents) and the surface of oxide particles, or between thiol-based compounds and the surface of metal particles, quantum dots or semiconductor particles.
- the particles should be stable (i.e., physically and chemically stable) prior their injection in a subject (unless specified that the particles should degrade in vivo).
- the particles When the particles are in suspension (i.e., dispersed in solution), typically prior injection, they should form a stable suspension.
- a suspension is considered as stable in the absence of observed sedimentation of the particles (i.e., the appearance of the suspension is homogeneous) within typically 1 minute, 2 minutes or 3 minutes following manual agitation of the suspension.
- the supernatant solution collected by any means and free of particles should present no or a very low amount of elements constituting the particles and/or constituting the particles’ surface coating (i.e. the detected amount of elements should be in the limit of resolution of the technic selected for quantifying these elements which are well-known by the skilled person in the art such as the ICP-MS (inductively coupled plasma - mass spectrometry) or the ICP-OES (inductively coupled plasma - optical emission spectrometry) technics).
- ICP-MS inductively coupled plasma - mass spectrometry
- ICP-OES inductively coupled plasma - optical emission spectrometry
- the surface of the particles is typically hydrophilic or hydrophobic.
- An hydrophilic surface ensures the wettability of the particles in aqueous medium and the possibility to obtain a water suspension.
- an hydrophobic surface is not wet by water.
- a particle with an hydrophobic surface can be wet by biological entities (such as proteins absorption on the surface of the hydrophobic particles), present in the biological medium.
- Particles contact angles with water measurement represents a typical wettability measurement to assess particles’ hydrophobicity. In such measurement, particles are dispersed in ultrapure water and left to dry on a substrate to create a homogeneous layer of particles. The contact angle measurement is performed with water as probe liquid, at room temperature.
- Typical hydrophobic particles have a contact angle with water above about 50°, preferably above about 60°, 70°, 80° or 90°.
- Typical hydrophilic particles have a contact angle with water below about 30°, preferably below about 25°, 20° or 10°.
- the particles When the particles are hydrophilic and have a size typically below about 20 pm, preferably below about 10 pm, they have typically a surface charge below about +30 mV to avoid any potential in vivo toxicity triggered by the surface charge.
- the surface charge is typically measured through the so-called zeta potential of the particles, the particles being in a water solution (i) at pH between about 6.5 and about 7.5, (ii) at a particles’ concentration between 0.5 g/kg and 10 g/kg (weight/weight), the particles concentration being typically measured by dry extract (i.e.
- the suspension containing the particles is typically placed at a temperature between 100°C and 250°C for a period typically comprised between 15 minutes and overnight) or by ICP-MS or ICP-OES and (iii) at an ionic strength presenting an electrical conductivity typically between about 0.01 pS/cm and about 2000 pS/cm at a temperature between about 15°C and about 25°C.
- inventors herein describe particles for use for treating a subject suffering of a disease, disorder or dysfunctional state as herein described via an acupuncture effect, when particles stably interact with biological cells, free nerve endings, end-organs, nerve fibers and/or sarcous sensory receptors of at least one acupoint or NAU of the subject.
- preferred particles have a size below 100 pm and are prepared from a material selected from a piezoelectric material, a pyroelectric material and a far-infrared radiation emitting -material.
- Treatment refers to both therapeutic and prophylactic or preventive treatment or measures able to alleviate or cure a disease, disorder or dysfunctional state.
- a treatment is intended for a mammal subject, preferably a human subject, in need thereof, whatever its age or sex.
- diseases encompasses inflammatory and infection diseases, disorders or dysfunctional state, for example inflammatory bowel disease, appendicitis, peptic ulcer, gastric ulcer, duodenal ulcer, peritonitis, pancreatitis, ulcerative colitis, pseudomembranous colitis, acute colitis, ischemic colitis, diverticulitis, epiglottitis, achalasia, cholangitis, cholecystitis, hepatitis, Crohn's disease, enteritis, Whipple's disease, allergy, anaphylactic shock, immune complex disease, organ ischemia, reperfusion injury, organ necrosis, hay fever, sepsis, septicemia, endotoxic shock, cachexia, hyperpyrexia, eosinophilic granuloma, granulomatosis, sarcoidosis, septic abortion, epididymitis, vaginitis, prostatitis, urethritis, chronic o
- treatment is performed in a subject suffering from type 2 diabetes, inflammatory bowel diseases including typically ulcerative colitis and Crohn’s disease, chronic obstructive pulmonary disease, depression, rheumatoid arthritis or psoriatic arthritis.
- inflammatory bowel diseases including typically ulcerative colitis and Crohn’s disease, chronic obstructive pulmonary disease, depression, rheumatoid arthritis or psoriatic arthritis.
- the acupoint or the scalp acupuncture line is selected from LU1, LU2, LU3, LU4, LU5, LU6, LU7, LU8, LU9, LU10, LU11, LI1, LI2, LI3, LI4, LI5, LI6, LI7, LI8, LI9, LI10, LI11, LI 12, LI13, LI14, LI15, LI16, LI17, LI18, LI19, LI20, ST1, ST2, ST3, ST4, ST5, ST6, ST7, ST8, ST9, ST10, ST11, ST12, ST13, ST14, ST15, ST16, ST17, ST18, ST19, ST20, ST21, ST22, ST23, ST24, ST25, ST26, ST27, ST28, ST29, ST30, ST31, ST32, ST33, ST34, ST35, ST36, ST37, ST38, ST39, ST40, ST41, ST42, ST43, ST44, ST45, SP1, SP2, SP3, SP4, SP5, SP6, SP7, SP8,
- acupoints or scalp acupuncture lines are activated during a protocol/method as herein described such as at least 2 acupoints or scalp acupuncture lines, for example 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 acupoints or scalp acupuncture lines, said lines being selected from MSI, MS2, MS3, MS4, MS5, MS6, MS7, MS8, MS9, MS10, MS11, MS12, MS13 and MS14.
- acupoint may be selected from): BL10, BL11, BL13, BL14, BL15, BL18, BL20, BL22, BL23, BL36, BL40, BL54, BL56, BL60, BL62, CV4, CV6, CV12, CV17, EX-B1, EX-LE2, EX-LE4, EX-LE5, EX-UE4, EX-UE9, GB12, GB20, GB21, GB25, GB30, GB31, GB33, GB34, GB39, GB40, GV4, GV14, GV20, HT5, HT7, KI3, KI6, KI10, KI13, LI4, LI5, LI11, LI15, LI18, LR3, LU1, LU9, PC6, SI3, SI4, SI9, SI11, SP4, SP6, SP9, SP10, ST5, ST25, ST28, ST
- acupoint In the context of rheumatoid arthritis, the following acupoints are preferred (i.e., a preferred acupoint may be selected from): BL11, BL18, BL20, BL23, BL36, BL54, BL56, BL60, BL62, CV4, CV6, CV12, EX-LE2, EX-LE4, EX-LE5, EX-UE4, EX-UE9, GB20, GB25, GB30, GB31, GB33, GB34, GB39, GB40, GV4, GV14, GV20, HT7, KI3, KI6, KI10, KI13, LI4, LI5, LI11, LI15, LR3, PC6, SI3, SI4, SI9, Sill, SP6, SP9, SP10, ST5, ST25, ST34, ST36, ST41, TE4, TE5 and TE14 [Pei-Chi Chou et al. Clinical efficacy of acupunctur
- acupoints are preferred (i.e., a preferred acupoint may be selected from): ST35, EX-LE5, GB34, SP9, GB39 and SP6 [X. Chen et al. The modulation effect of longitudinal acupuncture on resting state functional connectivity in knee osteoarthritis patients. Mol Pain (2015) 11:67]
- acupoint In the context of inflammatory bowel disease, the following acupoints are preferred (i.e., a preferred acupoint may be selected from): BL18, BL20, BL21, BL23, BL25, CV4, CV12, GV4, GV20, GV26, LI4, LI11, LR3, PC6, SP4, SP9, SP14, SP15, ST21, ST25, ST36, ST37, ST39 and TE5 [Gengqing Song et al. Acupuncture in Inflammatory Bowel Disease. Inflamm. Bowel Dis.
- acupoints are preferred (i.e., a preferred acupoint may be selected from): CV6, CV12, KI13, LI4, LI11, LR3, SP4, SP6, ST25, ST36 and ST37 [Chun-Hui Bao et al. Randomized controlled trial: Moxibustion and acupuncture for the treatment of Crohn’s disease. World J Gastroenterol 2014 August 21; 20(31): 11000-11011]
- acupoint In the context of diabetes type II, the following acupoints are preferred (i.e., a preferred acupoint may be selected from): BL13, BL14, BL20, BL22, BL23, CV4, CV12, KI13, LI4, LI11, SP6, ST28, ST36 and TE5 [ClinicalTrials.gov Study NCT04076800 ; Acupuncture and Insulin Doses in Insulin- treated Type 2 Diabetes (ACUDIA)] .
- acupoint In the context of chronic obstructive pulmonary disease (COPD), the following acupoints are preferred (i.e., a preferred acupoint may be selected from): LU1, LU9, LI18, KI3, GB12, BL13, BL20, BL23, CV4, CV12, CV17, EX-B1 and ST36 [Masao Suzuki et al. A Randomized, Placebo-Controlled Trial of Acupuncture in Patients With Chronic Obstructive Pulmonary Disease (COPD). Arch Intern Med. 2012; 172(l l):878-886; Ken SL Lau et al. A single session of Acu-TENS increases FEV1 and reduces dyspnoea in patients with chronic obstructive pulmonary disease: a randomised, placebo-controlled trial. Australian Journal of Physiotherapy 54: 179-184]
- acupoints are preferred (i.e., a preferred acupoint maybe selected from): HT7, LI4, ST36, SP6, LR3 andGV20 [ClinicalTrials.gov Study NCT01633996]
- particles interact with at least one, preferably several or all, of the following acupoints: BL23, GB34, KI3, LI4, LI11 and ST36.
- the particles interact with at least one and up to ten acupoints, for example 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 acupoints.
- the description also relates to a composition for use for treating a subject suffering of a disease, disorder or dysfunctional state as herein described.
- the composition comprises particles and the therapeutic effect is obtained via an acupuncture effect when the particles stably interact with biological cells, free nerve endings, end-organs, nerve fibers and/or sarcous sensory receptors present (in the biological medium of) at least one acupoint or NAU of the subject.
- preferred particles have a size below 100 pm and are prepared from a material selected from a piezoelectric material, a pyroelectric material and a far-infrared emitting -material.
- a particular composition comprises between about lmg/lOOg (particles weight/dispersion medium weight) and 40g/100g particles, preferably between about lg/lOOg and lOg/lOOg particles.
- the description further relates to a method for delivering acupuncture to a subject in need thereof.
- the method typically comprises a step of administering the particles, or a composition comprising the particles, to at least one acupoint or Neural Acupuncture Unit (NAU) of the subject, thereby triggering an acupuncture effect in the subject.
- NAU Neural Acupuncture Unit
- the method typically comprises a step of administering the particles, or a composition comprising the particles, to at least one acupoint or Neural Acupuncture Unit (NAU) of the subject, and a step of stimulating said particles by a skin massage on the at least one acupoint or NAU, thereby triggering an acupuncture effect in the subject.
- NAU Neural Acupuncture Unit
- the method typically comprises a step of administering the particles, or a composition comprising the particles, to at least one acupoint or Neural Acupuncture Unit (NAU) of the subject, and a step of stimulating said particles by heating the surface of the skin of the subject above the acupoint or NAU, thereby triggering an acupuncture effect in the subject.
- NAU Neural Acupuncture Unit
- the description also relates to a method for treating a subject in need thereof via an acupuncture effect.
- the method typically comprises a step of administering the particles, or a composition comprising the particles, to at least one acupoint or Neural Acupuncture Unit (NAU) of the subject, thereby treating the subject.
- NAU Neural Acupuncture Unit
- the method typically comprises a step of administering the particles, or a composition comprising the particles, to at least one acupoint or Neural Acupuncture Unit (NAU) of the subject, and a step of stimulating said particles by a skin massage on the at least one acupoint or NAU, thereby treating the subject.
- NAU Neural Acupuncture Unit
- the method typically comprises a step of administering the particles, or a composition comprising the particles, to at least one acupoint or Neural Acupuncture Unit (NAU) of the subject, and a step of stimulating particles by heating the surface of the skin of the subject above the acupoint or NAU, thereby treating the subject.
- NAU Neural Acupuncture Unit
- Particles are typically formulated in a liquid or in a gel, in particular in a liquid that turns into a gel when administered on at least one acupoint or NAU of the subject.
- a particular composition of the invention comprising particles is in the form of a liquid or a gel, in particular in a liquid form that turns into a gel when administered on at least one acupoint or NAU of the subject.
- the liquid-to- gel transition typically occurs between 30°C and 40°C.
- Poly(D,L-lactic acid-co-glycolic acid)-A poly(ethylene glycol)-ft-poly(D,L-lactic acid-co-glycolic acid) (PUGA-PEG-PUGA) triblock copolymers typically are materials which exhibit a sol-gel transition upon heating.
- the liquid-to-gel transition temperature is typically affected by the following parameters: the concentration of copolymer, the chain length of PEG, the chain length of PLGA, the molar ratio between PEG and PLGA, or the lactic acid/glycolic acid (LA:GA) ratio within the PLGA. All these parameters can be easily adjusted by the skilled person to trigger a liquid-to-gel transition at a temperature typically comprised between 30°C and 40°C, for example at the human body temperature.
- the herein defined particles are typically part of a composition which is a liquid or a gel, in particular a liquid having a liquid-to-gel transition temperature between 30°C and 40°C.
- a preferred composition for use for treating a subject suffering of disease as herein described is in a liquid or gel form, in particular in the form of a liquid having a liquid-to-gel transition temperature between 30°C and 40°C.
- a controlled release of the particles at the site of administration can be obtained by an adaptation of the gel according to methods well-known by the skilled person in the art.
- a controlled release of the particles typically between few seconds (for example about two seconds) and 1 week, can be obtained.
- a controlled release of the particles typically between 1 hour and 1 week, can be obtained.
- the affinity between the particles and the gel is typically characterized by the type of bonding existing between the particles and the material constituting the gel.
- the bonding can typically be an hydrogen bonding, a bonding resulting from electrostatic interactions, a complexing bonding or a chemically cleavable covalent bonding.
- the degradation of the gel typically consists in the swelling (i.e., expansion) of the gel or the breaking of bonds in the material(s) constituting the gel.
- the gel is ideally biodegradable.
- a biodegradable gel can typically comprises hydrolytic degradable polyesters blocks, such as poly(s- caprolactone) (PCL) blocks and poly(D,L-lactide- co-glycolide) (PLGA), blocks.
- the biodegradable gel can comprise polymer blocks with enzymatically degradable peptides, such as poly(L- alanine) (PA) blocks and chitosan blocks.
- PA poly(L- alanine)
- the particles or composition comprising such particles can be directly administered on at least one acupoint or NAU using typically a syringe and a needle when particles are in suspension (i.e., when they are formulated as a liquid or as a gel, provided the viscosity of the gel remains compatible with such administration mode, for example as a liquid that turns into a gel when administered in a subject).
- the particles can also be deposited on the surface of the skin. Particles will penetrate in the dermis and epidermis for example spontaneously or by massage. In this particular cases, hydrophobic particles are preferred.
- the particles can be directly stuck to the surface of a needle and the particles are released in the biological medium typically between few seconds (typically at least two seconds) and 10 minutes following needle insertion into the skin typically up to the dermis and/or the hypodermis layer.
- the particles can be formulated as a gel which stuck to the surface of a needle, the gel being released in the biological medium typically between few seconds and 10 minutes upon needle insertion in vivo.
- a linker agent containing a chemical cleavable bond or a UV cleavable bond can typically be used.
- This linker agent binds the particle or the gel containing the particles to the surface of the needle.
- the linker agent is typically a linker agent containing a chemical cleavable bond such as a cleavable disulphide bond, a cleavable ester bond, or a cleavable hydrazone bond.
- the particles can become the principal component of the needle(s), microneedle(s), or of the tip(s) of the needle(s) or microneedle(s).
- the needle(s), microneedle(s), or the tip(s) of the needle(s) or microneedle (s) is(are) inserted in vivo and remain(s) there.
- the erosion (such as degradation or dissolution) of the needle(s), microneedle(s) or of the tip(s) of the needle(s) or microneedle(s) triggers the release of the particles, typically within seconds (for example about 2 seconds), hours, days or weeks following needle(s) or microneedle(s) insertion/ implantation in the skin.
- Dissolvable needle(s) or microneedle(s) or dissolvable tip(s) of the needle(s) or microneedle(s) typically comprise(s) water soluble polymers, such as polyvinyl alcohol, polyvinylpyrrolidone or polyvinyl acetate, sugars, or any mixture thereof.
- the dissolvable needle(s) or microneedle(s) or tip(s) of needle(s) or microneedle(s) comprise(s) the herein described particles.
- needle insertion is that observed in the context of acupuncture.
- the volume occupied by particles on at least one acupoint or NAU location is typically comprised between about 0.001 mm 3 (i.e., 0.001 pL) and about 100 mm 3 (i.e., 100 pL), preferentially between about 0.005 mm 3 , about 0.01 mm 3 , about 0.05 mm 3 , about 0.1 mm 3 , about 0.2 mm 3 , about 0.5 mm 3 , about 1 mm 3 , about 2 mm 3 , or about 5 mm 3 , and about 10 mm 3 , about 20 mm 3 , or about 50 mm 3 .
- the volume occupied by the particle corresponds to the minimum volume measured in vivo (typically using imaging technics well known by the skilled person) which includes all the administered, typically injected, particles. Because the particles remain at their administration site, the volume occupied by the particle corresponds to the administered volume (e.g., the volume of the administered liquid or gel, or the volume of the needle, microneedle or tip of the needle or microneedle which has dissolved).
- the administered volume e.g., the volume of the administered liquid or gel, or the volume of the needle, microneedle or tip of the needle or microneedle which has dissolved.
- Needle(s) or microneedle(s) which can be used to administer/inject the particles at the acupoint or NAU have typically the following dimensions: a diameter typically between about 0.10 mm, or more than about 0.10 mm, and about 0.50 mm or about 0.40 mm, and a length typically between about 1 mm, about 1.5 mm, about 2 mm, or about 5 mm and about 100 mm.
- the concentration of particles on at least one acupoint or NAU is typically between 1 mg/lOOg (weight of particles by weight of biological medium) and 40 g / lOOg. Because the particles remain at their administration site, the concentration of particles on at least one acupoint or NAU corresponds to the concentration of particles which is present in the suspension (i.e., the dispersion medium) to be administered in vivo (e.g., the concentration of particles in the liquid or gel, or the concentration of particles in the needle, microneedle or tip of the needle or microneedle).
- the present invention is typically for use for treating a subject suffering of an inflammatory or infection disorder via an acupuncture effect.
- particles can be combined with anti inflammatory agent(s), anti -infectious agent(s) and/or pain relief agent(s).
- the anti-inflammatory agent is for example a nonsteroidal anti-inflammatory agent such as diclofenac, ibuprofen or aspirin.
- the anti-infectious agent is for example an agent from the cephalosporin, penicillin, fluoroquinolone, carbapenem or macrolide class.
- the pain relief agent is for example an analgesic agent such as acetaminophen, or an opioid agent such as morphine.
- agents can be administered for example orally, topically, or by local administration, typically by injection, at the site of inflammation.
- These agents can be administered before, concomitantly or after a treatment method comprising a step of administering the herein described particles, or concomitantly or after particles’ activation/stimulation when a massage or heat treatment step is required by the material the selected particles are made of.
- the agent(s) and particles are present in the same composition, typically in a composition as herein described, and administered simultaneously to the subject, for example topically.
- particles are combined with an anti-cancer agent such as for example a chemotherapeutic agent or an immunotherapeutic agent, and/or are administered to a subject suffering of a cancer and treated locally by surgery or by radiotherapy. Such a combination may improve the prognosis of cancer patients by promoting anticancer immunity in the patients.
- the particles can be administered on at least one acupoint or NAU more than once. However, they are preferably designed to be administered only once. In terms of invasiveness and detrimental effects/ risk linked to the administration procedure, a single administration of the particles of the invention is advantageous when compared to repeated needles implantation on at least one acupoint or NAU, which is typically required in the context of a treatment, especially in the context of chronic disorders.
- the treatment via activation/stimulation of particles, typically, as taught herein above, by skin massage when particles are prepared from a piezoelectric material and by skin heating when the particles are prepared from a pyroelectric material
- the treatment can be applied at least once per day, typically two-, three-, for-, five-, six-, seven-, eight-, nine- or ten-times per day, and during at least one day, typically two days, three days, four days, five days, six days, one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, or eight weeks.
- the treatment can be applied on a regular basis (i.e., every day or every week), or it can be sequenced in periods (typically days or weeks). For instance, the treatment period can last for one month, two months, three months, four months, five months, six month or seven months, where the input energy source is applied once a day, twice a day or three-times a day, 1 day, 2 days, 3 days, 4 days or five days per week.
- the stimulation duration is typically between 1 minutes and 60 minutes, preferably between 1 minute and 30 minutes, 1 minute and 15 minutes, 1 minute and 10 minutes, or 1 minute and 5 minutes, for example between 5 seconds, 10 seconds, 15 seconds or 30 seconds and 1 minute, 2 minutes, 3 minutes, 4 minutes or 5 minutes.
- a heating step of the surface of the skin of the subject above the acupoint(s) or NAU(s) is performed to stimulate the particles located on said acupoint(s) or NAU(s).
- one or several cycle(s) of temperature is/are performed depending on the composition of the particles. The temperature during each cycle typically does not exceed about 40°C in order to avoid skin burning.
- a cooling step is added to any protocol including a heating step in order to induce a thermic shock which will further enhance the effects of the following heating step applied to the particle, i.e., which will enhance the activation of the cooled particle when reheated.
- the particles are prepared from a material selected from a piezoelectric material or a pyroelectric material
- the number of times per day or per week the treatment should be applied, the frequency of stimulation, its duration, and possibly the intensity of stimulation are typically parameters that can be delivered to the subject according to a pre-established protocol.
- the particles used in the context of the present invention facilitate the follow up of the treatment, and are in particular advantageously used in the context of chronic diseases.
- the protocol may typically be adjusted upon measuring blood biomarkers (as detailed herein below) when these biomarkers are usable to monitor the disease status in a subject under treatment.
- the treatment/protocol can then be adjusted/modulated, for example increased or decreased, for example by increasing or reducing the number of times per day or per week the treatment is to be applied, and/or by increasing or reducing the treatment session duration.
- a panel of serum cytokines can be advantageously measured, typically in the blood.
- the panel for example comprises IL-6, IL-10, IL- 12p70, IL-13, IL-la, IL-Ib, IL-2, IL-4, IL-8, IL-5, IL-17, IL-23 and/or TNF.
- HMGB1, C-reactive protein (CRP), vascular endothelial growth factor (VEGF), white blood cell (WBC), platelet, or intercellular adhesion molecule 1 (ICAM-1) can be used each one independently, or in combination, as marker(s) of inflammation.
- IL-6 serum level may be measured in a subject under treatment to assess/monitor the inflammatory or infection disorder evolution. A decreased IL-6 serum level in a patient who responds to therapy is typically correlated with a positive response to treatment of the treated subject.
- Figure 1 Biological components, i.e., biological cells, free nerve endings, end-organs, nerve fibers and/or sarcous sensory receptors at acupoint or Neural Acupuncture Unit (NAU).
- NAU Neural Acupuncture Unit
- the epidermis comprises the stratum comeum (nonviable epidermis) layer, the stratum lucidum (viable epidermis) layer, the stratum granulosum (viable epidermis) layer, the stratum spinosum (viable epidermis) layer, and the stratum basal (viable epidermis) layer.
- the epidermis comprises the following biological cells: the keratinocytes which represent 95% of cells and are present in each layer, and the melanocytes, the Merkel cells, and the Langerhans cells which represent 5% of the remaining cells and are present in viable epidermis.
- the epidermis also comprises the following appendages: hairs (hairy skin), sweat glands, sebaceous glands, and lipids.
- the dermis comprises the following biological cells: fibroblasts, mast cells, macrophages, lymphocytes and platelets.
- the dermis also comprises the following appendages: collagen fibrils, elastic connective tissue, mucopolysaccharides, highly vascularized network, lymph vessels, sensory nerves/nerve fibers, free nerve endings, end-organs such as Pacinian corpuscles, Meissner corpuscles, Ruffini corpuscles and/or longitudinal lanceolate endings, hair follicles, sebaceous gland and sweat glands.
- the hypodermis comprises lipocytes. It also comprises the following appendages: loose connective tissue (lipocytes, collagen, elastin fibers), blood vessels, nerves and muscle spindles.
- Particles can be manufactured/synthesized according to synthesis methods described in the literature. Characterization of these “as synthesized particles” typically includes the analysis of particles size, composition and structure, the analysis of the composition and surface charge of the particles’ surface, as well as the analysis of the hydrophilic or hydrophobic behavior of the particles.
- Each test treatment method comprises a step of administering the particles on least one acupoint or NAU of the subject to be treated and, when the particles are prepared from a material selected from a piezoelectric material or a pyroelectric material, a subsequent step comprising the stimulation of the particles by a skin massage or a skin heating respectively.
- the following groups/conditions are typically tested to assess the efficiency of the treatment:
- Control group n° 1 healthy / no treatment
- Control group n°2 healthy / particles’ injection on at least one acupoint but no activation
- Control group n°3 diseased / treatment by acupuncture, typically electroacupuncture, transcutaneous electrical nervous stimulation (TENS), percutaneous electrical nervous stimulation (PENS), or any other bioelectronic medicine tool known to stimulate peripheral nerves such as the invasive vagus nerve stimulation;
- acupuncture typically electroacupuncture, transcutaneous electrical nervous stimulation (TENS), percutaneous electrical nervous stimulation (PENS), or any other bioelectronic medicine tool known to stimulate peripheral nerves such as the invasive vagus nerve stimulation;
- Test Group n°l diseased / injection of particles prepared from a far-infrared radiation-emitting material on at least one acupoint but no activation; - Test Group n°2: diseased / injection of particles on at least one acupoint and when the particles are prepared from a material selected from a piezoelectric material or a pyroelectric material, a subsequent step comprising the stimulation of the particles by a skin massage or a skin heating respectively.
- a LPS-induced cytokine release mouse model can typically be used as a mouse model of sepsis to monitor serum biomarkers under different conditions.
- mice models of Rheumatoid Arthritis, diabetes, or Inflammatory Bowel Disease can typically be used to monitor biomarkers such as cytokines.
Abstract
The present invention relates to particles and compositions comprising such particles for use for treating a subject suffering of a disease via an acupuncture effect when particles stably interact with biological cells, free nerve endings, end-organs, nerve fibers and/or sarcous sensory receptors of at least one acupoint or Neural Acupuncture Unit of the subject. The particles used in the context of the present invention are preferably below 100 µm and are preferably prepared from a material selected from a piezoelectric material, a pyroelectric material and a far-infrared radiation-emitting material.
Description
PARTICLES FOR THERAPEUTIC PURPOSES
The present invention relates to particles and compositions comprising such particles for use for treating a subject suffering of a disease via an acupuncture effect when particles stably interact with biological cells, free nerve endings, end-organs, nerve fibers and/or sarcous sensory receptors of at least one acupoint or Neural Acupuncture Unit (NAU) of the subject. The particles used in the context of the present invention are preferably below 100 pm and are preferably prepared from a material selected from a piezoelectric material, a pyroelectric material and a far-infrared radiation-emitting material.
BACKGROUND
Characteristic features of immunity, innate and/or adaptive, encompass the detection of immunogenic stimuli, the generation of protective responses and the formation of immunological memory. In this context, the activation of macrophages, dendritic cells, neutrophils, natural killers and other immune cells is pivotal in inflammation to restore tissue homeostasis. Macrophages and dendritic cells function as antigen-presenting cells and bridge innate and adaptive immune response. Upon antigen exposure, T and B lymphocytes undergo cell division and maturation and play key roles in antigen- specific adaptive immunity. The release of cytokines, chemokines and other inflammatory mediators amplifies the inflammatory process. This pro-inflammatory release is accompanied by the release of anti-inflammatory molecules, including IL-10 and soluble cytokine receptors and inflammation is classically resolved by the coordinated action of these pro-resolving mediators. In some conditions, however, excessive and unresolved inflammation can mediate tissue damage and lead to lethal and debilitating inflammatory diseases. In addition, unbalanced T- and B-cell-mediated processes associated with defects in antigen recognition, effector activity and immunologic memory may result in aberrant immune responses [Pavlov V.A. et al. Neural regulation of immunity: molecular mechanisms and clinical translation. Nature Neuroscience 2017, 20(2), 156-166]
Interestingly, researches have revealed that pattern-recognition receptors and cytokine receptors are expressed on neurons. As well, receptors for acetylcholine and other neurotransmitters are expressed on macrophages, dendritic cells and other immune cells. Peripheral immune cells also synthesize and release acetylcholine, catecholamines and other molecules classically identified as neurotransmitters [Menna R. Clatworthy et al. The nervous spleen. Immunology and Cell Biology, 2008, 86, 1-2]
It has been discovered that neuronal circuits operate reflexively and regulate innate and adaptive immunity. A neural reflex (i.e., a neuronal circuit operating reflexively) is defined by three components: first, a sensory receptor capable of responding to a change in the environment; second, a sensory afferent arc that transmits action potentials into the nervous system; and third, a motor efferent arc that sends action potentials from the nervous system back to the periphery to modulate environment. Known neural reflex circuitry involved in immunity are the inflammatory reflex, the vagus nerve-adrenal reflex, the
enteric-neural reflex, the neural reflex in cancer, the gateway reflex, the nociceptive reflex in the lung, the axon-axon reflex [S.S. Chavan et al. Essential Neuroscience in Immunology. The Journal of Immunology. 2017; 198:3389-3397; K.J. Tracey. Reflexes in Immunity. Cell 164, January 28, 2016; 343]
One particularly well-characterized neuronal circuit regulating innate immunity is the inflammatory reflex, a neural reflex circuit of action potentials traveling in the sensory and motor vagus nerves that regulate cytokine production in the spleen. The efferent action potentials traveling down the vagus nerve culminate in the celiac ganglion, the site of origin of adrenergic splenic nerve. The splenic nerve is adrenergic, producing norepinephrine in the vicinity of lymphocytes in the spleen. A discreet subset of lymphocytes regulated by splenic nerve signal express choline acetyltransferase, the rate limiting enzyme in the biosynthesis of acetylcholine. Acetylcholine released by lymphocytes under the control of adrenergic splenic nerve signals inhibits macrophage cytokine release and shifts them toward an M2 anti-inflammatory tissue protective phenotype. Acetylcholine-induced signal transduction in monocytes and macrophages is mediated by a-7 nicotinic acetylcholine receptors which inhibit the nuclear translocation ofNF-kB, activate the JAK2/STAT3 pathway, stabilize mitochondrial membranes, and downregulate the activity of the inflammasome. The net-effect of vagus nerve-mediated signals within the spleen is the inhibition of cytokine release by the red pulp and marginal zone macrophages, which together account for 90% of the TNF and IF-1 produced during typically acute endotoxemia [Kevin J. Tracey. The inflammatory reflex. Nature, 2002. 420, 853-859; Valentin A. Pavlov etal. Neural regulation of immunity: molecular mechanisms and clinical translation. Nature Neuroscience. 2017, 20(2), 156-166; Sangeeta S. Chavan et al. Essential Neuroscience in Immunology. The Journal of Immunology. 2017, 198, 3389-3397; J.M. Huston et al. The inflammatory reflex and neural tourniquet: harnessing the healing power of the vagus nerve. Bioelectron. Med., 2018; 1(1); 29-38]
In this context, the bioelectronic medicine that stimulate the peripheral nervous system has been used to treat injury and disease. The bioelectronic medicine utilize tools to interface with the nervous system to modulate and control the immune response and the physiological state of organs and systems. In fact, communication within the neural network occurs via electrical signals that travel rapidly and specifically along nerves. Upon reaching their intended cellular and molecular targets, these electrical signals cause the release of neurotransmitters. Through targeted manipulation of the neural signals (i.e., communication within the neural network), bioelectronic medicine harnesses endogenous pathways for therapeutic purposes.
Invasive vagus nerve stimulation is currently approved for the treatment of medically refractory epilepsy and depression and clinical trials are ongoing for the treatment of sepsis and inflammatory disorders, including rheumatoid arthritis and Crohn’s disease. [D. Fox. The electric Cure, Nature 2017; 545; 20-22] Opportunities of treatment when stimulating the vagus nerve using invasive vagus nerve stimulation encompasses inflammatory disorder including appendicitis, peptic ulcer, gastric ulcer, duodenal ulcer, peritonitis, pancreatitis, ulcerative colitis, pseudomembranous colitis, acute colitis,
ischemic colitis, diverticulitis, epiglottitis, achalasia, cholangitis, cholecystitis, hepatitis, Crohn's disease, enteritis, Whipple's disease, allergy, anaphylactic shock, immune complex disease, organ ischemia, reperfusion injury, organ necrosis, hay fever, sepsis, septicemia, endotoxic shock, cachexia, hyperpyrexia, eosinophilic granuloma, granulomatosis, sarcoidosis, septic abortion, epididymitis, vaginitis, prostatitis, urethritis, bronchitis, emphysema, rhinitis, pneumonitis, pneumonoultramicroscopicsilicovolcanoconiosis, alveolitis, bronchiolitis, pharyngitis, pleurisy, sinusitis, influenza, respiratory syncytial virus infection, HIV infection, hepatitis B virus infection, hepatitis C virus infection, herpes virus infection, disseminated bacteremia, Dengue fever, candidiasis, malaria, filariasis, amebiasis, hydatid cysts, bums, dermatitis, dermatomyositis, sunburn, urticaria, warts, wheals, vasculitis, angiitis, endocarditis, arteritis, atherosclerosis, thrombophlebitis, pericarditis, myocarditis, myocardial ischemia, periarteritis nodosa, rheumatic fever, Alzheimer's disease, coeliac disease, congestive heart failure, adult respiratory distress syndrome, meningitis, encephalitis, multiple sclerosis, cerebral infarction, cerebral embolism, Guillaume-Barre syndrome, neuritis, neuralgia, spinal cord injury, paralysis, uveitis, arthritides, arthralgias, osteomyelitis, fasciitis, Paget' s disease, gout, periodontal disease, rheumatoid arthritis, synovitis, myasthenia gravis, thyroiditis, systemic lupus erythematosus, Goodpasture's syndrome, Behcet's syndrome, allograft rejection, graft-versus-host disease, Type I diabetes, ankylosing spondylitis, Berger's disease, Reiter's syndrome and Hodgkin's disease (W02006073484).
However, invasive neurostimulation requires surgical implantation which may trigger unwanted side effects. Therefore, non-invasive approaches seem particularly advantageous as they can be administered more easily, and tolerated better [Huston J.M. et al. The inflammatory reflex and neural tourniquet: harnessing the healing power of the vagus nerve. Bioelectron. Med. (2018) 1(1), 29-38] Among them, transcutaneous electrical nervous stimulation (TENS) emerged as a promising approach, notably the transcutaneous vagus and trigeminal nerve stimulation through the ear (tVNS and TNV respectively) [B. Mercante et al. Auricular Neuromodulation: the Emerging Concept beyond the Stimulation of Vagus and Trigeminal nerves. Medicines, 2018; 5, 10; 3-12] However, skin represents an electrical barrier for transcutaneous electrical stimulation. Also, selectivity for stimulating specific nerve fibers and enhancing spatial resolution may be improved.
Therefore, transdermal nerve stimulation represents another alternative strategy which is minimally invasive for nerve stimulation. The percutaneous electrical nerve stimulation (PENS) is delivered by insertion of electrodes near the peripheral nerves which is to be stimulated. Wireless PENS has also been proposed. The Stimwave system, used for pain relief, typically involves an implant which comprises a stimulator and a micro-receiver, an electronic device (i.e., Wearable Antenna Assembly: WAA) used to power the receiver, the implanted receiver and stimulator only accepting power and parameter settings from a specific WAA, personalized for each patient, and a programmer (Apple watch, Apple Touch, IPad programmer). PENS represents a useful alternative for subjects who may not support
transcutaneous electrical stimulation or when wanting to avoid skin resistance. PENS is sometimes assimilated to electroacupuncture when the stimulation is given at an acupoint.
Alternatively, acupuncture (including manual acupuncture, electroacupuncture, pressure acupuncture, laser acupuncture and heat acupuncture) is an interesting approach performed by an acupuncturist for transdermal nerve stimulation. Clinical studies showed that acupuncture can improve post-operative recovery, osteoarthritis, migraine, joint pain, stroke, post-traumatic stress disorder and drug addiction [L. Ulloa et al. Nerve Stimulation: Immunomodulation and Control of Inflammation. Trends Mol. Med. 2017; 23(12); 1103-1120] Neuromodulation with acupuncture or electroacupuncture is endorsed by the WHO and NIH and it is used by millions of people to control pain, inflammation and to reestablish physiological homeostasis during illness. [L. Ulloa et al. Nerve Stimulation: Immunomodulation and Control of Inflammation. Trends Mol. Med. 2017; 23(12); 1103-1120] Vagus nerve stimulation via acupuncture has also been used to alter bowel function, gastric acidity and heart rate [K.J. Tracey. The Inflammatory Reflex. Nature, 2002; 420; 853-859] Activation of an anti inflammatory reflex involving the vagus nerve was described in endotoxemic rats using electroacupuncture at a point located at the junction of the first and the second metacarpal bones. In this reflex, somatosensory stimulation via unknown mechanism reaches the brain and triggers activation of muscarinic acetylcholine receptor-mediated signaling. This activation is linked with efferent vagus nerve activity and catecholaminergic signaling to the spleen, which results in suppression of serum TNF, IL-ip and IL-6 and in improved survival in lethal endotoxemia. Electroacupuncture at another acupuncture point causes stimulation of sciatic nerve activity in a voltage dependent manner. Signals arising in the sciatic nerve culminate on efferent vagus nerve signals. The efferent vagus nerves signals terminate on the release of dopamine in the adrenal medulla. Dopamine induced by sciatic nerve stimulation targets dopaminergic type 1 (Dl) receptors and suppresses systemic inflammation through D1 -receptor-mediated mechanism and results in improved survival of mice with cecal ligation and puncture-induced polymicrobial sepsis [V.A. Pavlov et al. Neural regulation of immunity: molecular mechanisms and clinical translation. Nature Neuroscience, 2017; 20(2); 156-166; S. S. Chavan et al. Regulating innate immunity with dopamine and electroacupuncture. Nature medicine 2014; 20(3); 239- 241; R. Torres-Rosas et al. Dopamine mediates vagal modulation of the immune system by electroacupuncture. Nature Medicine. 2014, 20, 291-295]
The world health organization (WHO) has published a report indicating diseases or disorders for which acupuncture therapy has been tested in controlled clinical trials reported in the recent literature and has produced a classification comprising the four following categories [Acupuncture: review and analysis of reports on controlled clinical trials. WHO, 2003]:
I Diseases, symptoms or conditions for which acupuncture has been proved - through controlled trials - to be an effective treatment. In this category, treatment for depression (including depressive neurosis and depression following stroke) and Rheumatoid arthritis are listed.
2_Diseases, symptoms or conditions for which the therapeutic effect of acupuncture has been shown but for which further proof is needed. In this category, treatment for Diabetes mellitus, non-insulin- dependent, osteoarthritis and schizophrenia are listed.
3_Diseases, symptoms or conditions for which there are only individual controlled trials reporting some therapeutic effects, but for which acupuncture is worth trying because treatment by conventional and other therapies is difficult. In this category, Pulmonary heart disease, Chronic (CCS) and Irritable (ICS) Colon Syndrome are listed.
4_Diseases, symptoms or conditions for which acupuncture may be tried provided the practitioner has special modem medical knowledge and adequate monitoring equipment. In this category, Coronary heart disease (angina pectoris) and Breathlessness in chronic obstructive pulmonary disease are listed. Furthermore, according to the WHO [WHO Standard Acupuncture Point Locations in the western pacific region, World Health Organization, 2008; A proposed standard international acupuncture nomenclature, Report of a WHO scientific Group, World Health Organization 1991], 14 meridians, 361 classical acupuncture points, 8 extra meridians, 48 extra points, and scalp acupuncture lines (also identified in the literature as “acupoints” or “APs”) are located on the surface of a human body. The proposed nomenclature for the 361 classical acupoints is listed under 14 meridians as follows: (1) lung meridian (LU) with 11 acupoints; (2) large intestine meridian (LI) with 20 acupoints; (3) stomach meridian (ST) with 45 acupoints; (4) spleen meridian (SP) with 21 acupoints; (5) heart meridian (HT) with 9 acupoints; (6) small intestine meridian (SI) with 19 acupoints; (7) bladder meridian (BL) with 67 acupoints; (8) kidney meridian (KI) with 27 acupoints; (9) pericardium meridian (PC) with 9 acupoints; (10) triple energizer meridian (TE) with 23 acupoints; (11) gallbladder meridian (GB) with 44 acupoints; (12) liver meridian (LR) with 14 acupoints; (13) governor vessel (GV) with 28 acupoints; (14) conception vessel (CV) with 24 acupoints. The proposed nomenclature for the 48 extra points consists of a prefix “EX” denoting “extra point” followed by an alphabetical code indicating the region (HN for head and neck, CA for chest and abdomen, B for back, UE for upper extremity and LE for lower extremity).
The World Health Organization (WHO) has presented a methodology for locating acupuncture points on the surface of a human body, as well as the location of 361 acupunctures points (acupoints) [WHO Standard Acupuncture Point Locations in the Western Pacific Region, 2008] Three methods are described for locating acupuncture points: The anatomical landmark method, the proportional bone (skeletal) measurement method (using the B-cun as standard measuring unit) and the finger-cun measurement method (using the F-cun as standard measuring unit). Complementary literature regarding acupoint location in human body can be found in the AACP Acupuncture Point Reference Manual 2015 [Evidence Based Acupuncture Training, Acupuncture in Physiotherapy, Western Medical Acupuncture for Musculoskeletal Pain Conditions, Course Handbook] .
Nerves, at the acupoints (APs), can be stimulated with different technique including pressure (acupressure), massage, heat (moxibustion for example), sound (sonopuncture) or electricity (electroacupuncture) .
Acupoints are specific points of the human body that have demonstrated mechanical hypersensitivity and have high electrical conductance. Sensory nerve endings are distributed unevenly over the body and acupoints have a higher density of sensory nerve endings than surrounding areas. Early studies in animals and human autopsies revealed that (the biological medium of) most acupoints contained abundant free nerve endings, encapsulated cutaneous mechanoreceptors (Merkel cells, Meissner, Ruffini and/or Pacinian corpuscles), sarcous sensory receptors (muscles spindles and tendon organs), and their afferent fibers. Many examined acupoints had relatively dense neural component, particularly nerves fibers, with a ratio nearly 1.4:1 compared to non-acupoint areas. The ratio of local myelinated to nonmyelinated fibers was found to be nearly 4-fold higher in human Zusanli (ST36) acupoint than in surrounding areas. Specific acupuncture points are also identified as Neural Acupuncture Unit (NAU) when stimulated with acupuncture needles. “NAU” designates the collection of local neural and neuroactive components distributed in the skin, muscle and collective tissues activated i) by an acupuncture needle that is inserted into a designated point on the body (an acupoint) and ii) exposed to a mechanical or electrical stimulation [Z.-J. Zhang et al. Neural Acupuncture Unit: A New Concept for Interpreting Effects an Mechanism of Acupuncture. Evidence-Based Complementary and Alternative Medicine, 2012; Article ID 429412] The legend of figure 1 indicates the biological components and biological cells which are typically present at an acupoint and/or NAU.
Recent studies have also suggested that acupoints associated with internal organs can be identified as neurogenic inflammatory spots occurring on the skin that are associated with visceral disorders. These cutaneous “neurogenic spots” function as therapeutic acupoints (i.e., electroacupuncture at neurogenic spots generates therapeutic effects like acupuncture effects), and are characterized by plasma extravasation and vasodilation in the postcapillary venules of the skin arising from release of calcitonin gene-related peptide (CGRP) and substance P (SP) from activated small diameter sensory afferents. These neurogenic spots can be visualized experimentally in the skin by systemic injection of Evans blue dye. Authors suggest that these “neurogenic spot” can be identified by non-invasive methods, such as infrared thermal imaging or electrodermal measurement [Do-Hee Kim et al. Acupuncture points can be identified as cutaneous neurogenic inflammatory spots. Scientific Report (2017) 7: 15214; Yu Fan etal. Enhanced spinal neuronal responses as a mechanism for increased number and size of active acupoints in visceral hyperalgesia. Scientific Report (2020) 10:10312 ].
Acupoint reflects the status of a visceral organ, and visceral disorders can be treated by manipulating acupoints. Acupoints or NAUs for which a large portion of surrounding biological components is made of muscle fibers include among other Zusanli (ST36), Hegu (LI4) and Huantiao (GB30). Acupuncture at the Zusanli (ST36) or at the Hegu (LI4) acupoint are typically shown to
modulate inflammatory responses in internal organs [H.-D. Lim el al. Anti-inflammatory effects of acupuncture stimulation via the vagus nerve. PLOS ONE, DOI: 10.1371/joumal.pone.0151882, 2016; V.A. Pavlov etal. Neural regulation of immunity: molecular mechanisms and clinical translation. Nature Neuroscience 20(2), 2017] Acupoints or NAUs for which a large portion of surrounding biological components is made of cutaneous receptors include acupoints located in the finger pads, palms, plantar area, and the surrounding lips such as Shaoshang (LU11) and Shuigou (GV26). Acupoints or NAUs for which a large portion of surrounding biological components is made of tendons organs, Ruffini corpuscles and Pacinian corpuscles include acupoints located around elbow, wrist, and ankle joints such as Chize (LU5), Daling (PC7), Dubi (ST35) and Jiexi (ST41).
Neuroactive components of NAUs are non-neuronal tissues and biological cells as well as the various mediators capable of modulating NAU afferent signals via local biochemical reactions which are released by these tissues and cells. In addition, biophysical reactions of NAUs are triggered by the activation of mechanoreceptors. Multiple central neural pathways convey NAU afferent impulses. A distributed network of widespread brain regions that respond to acupuncture provides the neural substrate for broad therapeutic effects of acupuncture. Clinical studies have revealed that acupuncture treatment was capable of normalizing abnormal neuroimaging activity in patients with Alzheimer’s disease, major depressive disorder, etc.. Typically, neuroimaging approaches such as functional magnetic resonance imaging (fMRI) and positron emission topography (PET) have been widely introduced into acupuncture research. Normalization of neuroimaging signals was correlated with clinical improvement. Moreover, acupuncture has broad effects on normalizing neurochemical and behavioral abnormalities in neuropsychiatric disorders as well as on regulating autonomic activities in visceral disorders. [Z.-J. Zhang el al. Neural Acupuncture Unit: A New Concept for Interpreting Effects and Mechanism of Acupuncture. Evidence-Based Complementary and Alternative Medicine, 2012; Article ID 429412]
The following Table 1 lists the main existing bioelectronic medical technologies used to treat diseases in relation with inflammation and infection. In this Table, the invasiveness of each of the herein above described technologies, its spatial and temporal resolution, its safety risk as well as its ability to offer autonomy to the subject receiving the treatment (i.e. ability of the subject to receive treatment without impact on daily activities), are criteria evaluated/estimated as follows: © (high negative impact on one or more criteria), © (moderate negative impact on one or more criteria), © (no negative impact on criteria).
Table 1:
*Manual acupuncture or electroacupuncture
**Heat acupuncture, sonopuncture, acupressure, laser acupuncture Table 1 illustrates the need to optimize the modulation of neural signals in order to mobilize the body immunity for therapeutic purposes.
The present invention provides a solution to this unmet need which advantageously satisfies all of the criteria listed above. Indeed, the herein below described invention is moderately invasive (similar to acupuncture’s invasiveness) and safe, offers optimal spatial and temporal resolution, and allows the subject to manage the therapeutic treatment without the physical help of a practitioner, typically of an acupuncturist.
SUMMARY OF THE INVENTION Inventors herein describe particles for use for treating a subject suffering of a disease via an acupuncture effect when particles stably interact with biological cells, free nerve endings, end-organs, nerve fibers and/or sarcous sensory receptors (present in the biological medium) of at least one acupoint or NAU of the subject, and to a composition for use for treating a subject suffering of a disease, wherein the composition comprises particles and the therapeutic effect is obtained via an acupuncture effect when particles interact with biological cells, free nerve endings, end-organs, nerve fibers and/or sarcous
sensory receptors (present in the biological medium) of at least one acupoint or NAU of the subject. Particles are preferably below 100 pm and are preferably prepared from a material selected from a piezoelectric material, a pyroelectric material and a far-infrared radiation-emitting material.
The description further relates to a method for delivering acupuncture to a subject in need thereof. When the particles are prepared from a material selected from a far-infrared radiation emitting-material, the method typically comprises a step of administering the particles, or a composition comprising the particles, to at least one acupoint or Neural Acupuncture Unit (NAU) of the subject, thereby triggering an acupuncture effect in the subject.
When the particles are prepared from a piezoelectric material, the method for treating a subject suffering of a disease via an acupuncture effect / for delivering acupuncture to a subject in need thereof typically comprises a step of administering the particles, or a composition comprising the particles, to at least one acupoint or Neural Acupuncture Unit (NAU) of the subject, and a step of stimulating said particles by a skin massage on the at least one acupoint or NAU, thereby triggering an acupuncture effect in the subject.
When the particles are prepared from a pyroelectric material, the method for treating a subject suffering of a disease via an acupuncture effect / for delivering acupuncture to a subject in need thereof typically comprises a step of administering the particles, or a composition comprising the particles, to at least one acupoint or Neural Acupuncture Unit (NAU) of the subject, and a step of stimulating said particles by heating the surface of the skin of the subject above the acupoint or NAU, thereby triggering an acupuncture effect in the subject.
The description also relates to a method for treating a subject in need thereof via an acupuncture effect. When the particles are prepared from a material selected from a far-infrared radiation emitting-material, the method typically comprises a step of administering the particles, or a composition comprising the particles, to at least one acupoint or Neural Acupuncture Unit (NAU) of the subject, thereby treating the subject.
When the particles are prepared from a piezoelectric material, the method typically comprises a step of administering the particles, or a composition comprising the particles, to at least one acupoint or Neural Acupuncture Unit (NAU) of the subject, and a step of stimulating said particles by a skin massage on the at least one acupoint or NAU, thereby treating the subject.
When the particles are prepared from a pyroelectric material, the method typically comprises a step of administering the particles, or a composition comprising the particles, to at least one acupoint or Neural Acupuncture Unit (NAU) of the subject, and a step of stimulating said particles by heating the surface of the skin of the subject above the acupoint or NAU, thereby treating the subject.
DETAILED DESCRIPTION OF THE INVENTION
Inventors herein describe particles for use for treating a subject suffering of a disease via an acupuncture effect when particles stably interact with biological cells, free nerve endings, end-organs, nerve fibers and/or sarcous sensory receptors (present in the biological medium) of at least one acupoint or Neural Acupuncture Unit (NAU) of the subject. Preferred therapeutic particles are below 100 pm, and are prepared from a material selected from a piezoelectric material, a pyroelectric material and a far-infrared radiation-emitting material.
The present invention optimizes the efficacy of treatments involving peripheral nerve stimulation while minimizing the detrimental effects/risk compared to existing treatments using bioelectronic approaches. In addition, it facilitates patient’s autonomy.
THERAPEUTIC PARTICLES: TEMPORAL AND SPATIAL RESOLUTIONS
The material constituting the particles of the invention as well as their structure are key to obtain the desired therapeutic efficacy. Indeed, the particle’s efficacy directly depends on the specific intrinsic property of the material constituting the particle. A careful selection of the composition and structure (i.e., an amorphous structure, a semi-crystalline structure or a crystalline structure) of the particles therefore optimizes the temporal energy input signal transduction and/or the temporal energy input signal modulation.
Piezoelectric particle
The particle of the invention can be a piezoelectric particle, typically a piezoelectric particle having a structure and/or composition capable of converting in vivo an external mechanical input signal into an internal electrical output signal.
When the particle is a piezoelectric particle, it typically consists of a quartz (S1O2) particle, a barium titanate (BaTiO,) particle, a AIN particle, a GaN particle, a ZnO particle, a boron nitride (BN) particle or a particle comprising or consisting in polyvinylidene fluoride polymer or a derivative thereof, polymeric L-lactic acid, polymeric D-lactic acid, DNA or M13 bacteriophage.
These piezoelectric particles, in contact with the peripheral nervous system on at least one acupoint and/or NAU, stimulate the peripheral nerves when activated by a skin massage on the acupoint or NAU. This stimulation of the nerve’s internal electrical signal is rendered possible by the intrinsic piezoelectric property of the particles selected for use in the context of the present invention which are “activated” when a skin massage is performed on the acupoint or NAU where the piezoelectric particles are located.
Pyroelectric particle
The particle of the invention can be a pyroelectric particle. When the particle is a pyroelectric particle, it is typically a UiTaCri particle or it is a particle comprising or consisting in PVDF polymer.
These pyroelectric particles, in contact with the peripheral nervous system on at least one acupoint and/or NAU, stimulate in vivo the peripheral nerves when activated. The activation is obtained by heating the surface of the skin of the subject above the acupoint or NAU where the pyroelectric particles are located. This stimulation of the nerve’s internal electrical signal is rendered possible by the intrinsic pyroelectric property of the particles selected for use in the context of the present invention which are “activated” when a step of heating the surface of the skin of the subject above the acupoint or NAU where the pyroelectric particles are located is performed.
Far-infrared radiation emitting particle
The particle of the invention can be a far-infrared radiation-emitting particle. When the particle is a far-infrared radiation emitting particle, it is typically an inorganic particle, preferentially a metal oxide particle with an emissivity level of more than 50%, preferably more than 60%, more than 70%, more than 80%, or more than 90%, and emitting between 4 microns and 200 microns, preferably between 4 microns and 50 microns, or between 4 microns and 20 microns. The inorganic particle capable of emitting far-infrared radiation is typically an AI2O3 particle, a Fe2C>3 particle, a MgO particle, a ZrC particle or a Y2O3 particle.
These far-infrared radiation emitting particles, in contact with the peripheral nervous system on at least one acupoint and/or NAU, stimulate/modulate in vivo the electrical signal. This signal is then conducted by said nerves up to the central nervous system (CNS). This stimulation/modulation of the nerve’s internal electrical signal is rendered possible by the intrinsic far-infrared radiation emitting property of the particles selected for use in the context of the present invention (i.e., an increase of the temperature at acupoint or NAU is obtained by converting radiation emitted by the particle into heat).
Particles have been selected by inventor for their ability to stably interact with biological entities present on at least one acupoint and/or NAU and to efficiently stimulate the peripheral nerves. The expression “stably interacting” indicates that particles (i) do not move after injection/administration on at least one acupoint or NAU, i.e. at least, preferably more than 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90%, even more preferably more than 80% or 90%, of the injected dose of particles remain at the site of injection, the particles interacting with elements of the biological medium present on the at least one acupoint or NAU and/or with the biological cells, i.e. they interact in particular with the membranes of the biological cells and/or are up taken by the biological cells, and (ii) do not degrade after injection/administration on the at least one acupoint or NAU unless expressly designed to experience in vivo degradation (for example via dissolution of the particle). By stably interacting with the biological
entities present on at least one acupoint and/or NAU, the particles ensure a high spatial resolution for signal transmission.
The biological cells of interest the particles are directly or indirectly stably interacting with at the site of injection (i.e., on the at least at one acupoint or NAU) typically comprise keratinocytes, melanocytes, Merkel cells, Langerhans cells, fibroblasts, mast cells, macrophages, lymphocytes, platelets and/or lipocytes. Particles also directly or indirectly stably interact with the other elements typically present in the biological medium of at least one acupoint or NAU, i.e., with free nerve endings, nerves fibers, sarcous sensory receptors and/or end-organs, the end-organs being typically Meissner corpuscles, Ruffini corpuscles, Pacinian corpuscles and/or longitudinal lanceolate endings.
To allow the required “stable interaction” state between the particles and the elements of the biological medium, for example the biological cells, at acupoint(s) or NAU(s), the two following particles’ features are to be properly selected: (i) the size of the particles and (ii) the composition of the particles’ core and/or of the particles’ surface coating.
(i) The size of the particles
In the context of the present invention, the particles’ size is typically below about 100 pm. A threshold limit of the particles’ size of about 200 nm has been observed regarding uptake and retrograde transport of particles following axonal delivery in cortical neuronal cells [Anna Uesniak el al. Rapid growth cone uptake and dynein-mediated axonal retrograde transport of negatively charged nanoparticles in neurons is dependent on size and cell type. Small, 2018, 1803758] Uptake and retrograde transport were observed for particles having a size up to 100 nm whereas they were hardly observed for particles having a size typically above about 200 nm. In the context of the present invention wherein the stable interaction between particles and elements of the biological medium including biological cells is required, the size of the particles is preferably between about 200 nm and about 100 pm.
The size of the particles is typically measured using well-known electron microscopic (EM) tools or light scattering tools.
When the particles are hydrophobic or hydrophilic and the size of the particles is at the microscale, i.e., between about 1 pm and about 100 pm, the size is typically measured using an electron microscopic technic, typically scanning electron microscopy. The longest dimension of the core of a particle (the core of the particle being the particle without any surface coating) measured in the electron microscopy image is reported. At least 100 particles of a population are measured in their longest dimension and the median size of the considered population of particles is calculated. In this context, the “size” of the particles designates the median size of the particles of a population comprising at least 100 particles.
When the particles are hydrophilic and the size of the particles is at the nanoscale, i.e., between about 1 nm and about 1000 nm, and when the particle size is monodisperse, i.e., the polydispersity index of the suspension of particles is found typically below 0.2, the size is typically measured using the Dynamic Light Scattering (DLS) technique. In the context of the DLS technic, the size of the particle is typically measured when the particles are in aqueous suspension (i) at a pH between about 6.5 and about 7.5, (ii) at a particles’ concentration between 0.5 g/kg and 10 g/kg (weight/weight), the particles’ concentration being typically measured by dry extract (i.e. the suspension containing the particles is typically placed at a temperature between 100°C and 250°C for a duration period typically comprised between 15 minutes and overnight) or by ICP-MS or by ICP-OES and (iii) at an ionic strength presenting an electrical conductivity typically comprised between about 0.01 pS/cm and about 2000 pS/cm at a temperature between about 15°C and about 25°C. When measured by DLS, the size of the particles corresponds to the size of the particles given in intensity.
Alternatively, the electron microscopy technique (EM), typically the transmission electron microscopy (TEM) or Cryo-TEM can be used to measure the size of the particles at the nanoscale. In this case, the longest dimension of a particle measured in the electron microscopy image is reported. At least 100 particles are measured in their longest dimension and a median size of the particles of the population comprising at least 100 particles is calculated. In this context, the “size” of the particles designates the median size of the particles of a population comprising at least 100 particles.
When the particle size is polydisperse (i.e., the polydispersity index of the suspension of particle is found typically above 0.2 when measured by DLS), a fractionation technique can be used to separate the populations of particles in different monodisperse particles’ size populations. Typically, a field flow fractionation tool can be used to reach this goal. The size of the particles in each population/fraction is determined as described herein-above using DLS or EM tools. In addition, in each population/fraction the quantity of particles is estimated. This estimation can typically be done by quantification of at least one element constituting the particle. The “size” of the particles represents in this context the average weight of the sizes of the particles obtained in each population of particles or fraction thereof.
The shape of particle is not critical for the invention. Typically, the particle can have an “inhomogeneous shape”. The expression “inhomogeneous shape” designates particle the sizes of which have been measured in the 3 dimension (x, y, z) and present one or two dimensions larger than the other(s), typically one or two dimensions more than about three times larger than the other(s). However, a particle with a homogeneous shape is preferred. The expression “homogeneous shape” designates particle the sizes of which have been measured in the 3 dimension (x, y, z) and present a ratio which does not exceed a factor 3 between each dimension (i.e., x/y < 3, y/z < 3 and z/x < 3).
Whatever the surface of the particles, they will most certainly end up within biological cells when their size is below about 20 pm or 10 pm. On the contrary, whatever the surface of the particles, they will be localized preferentially outside biological cells, typically in the biological medium surrounding the cells when their size is typically above about 10 pm or 20 pm.
Indeed, when the size of the particles is typically below 20 pm, the particles can enter cells by different mechanisms: through endocytosis-dependent pathways or direct cytoplasmic delivery [Nathan D. Donahue, et al. Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine. Advanced Drug Delivery Reviews 143 (2019) 68-96] Endocytic -dependent pathways encompass five mechanistically distinct classes: (a) clathrin-dependent endocytosis for particles’ size typically between about 100 nm and about 500 nm; (b) caveolin-dependent endocytosis for particles’ size typically between about 50 nm and about 100 nm; (c) clathrin- and caveolin-independent endocytosis; (d) phagocytosis, typically used by immune cells, including macrophages, dendritic cells, neutrophils, and B lymphocytes, for particles’ size typically up to about 20 pm, preferentially up to about 10 pm; and (e) micropinocytosis for particles’ size typically between about 0.5 pm and about 1.5 pm [Nathan D. Donahue, et al. Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine. Advanced Drug Delivery Reviews 143 (2019) 68-96]
Alternatively, direct injection of particles into the cytoplasm of biological cells present on at least one acupoint may be performed in the context of the present invention, the biological cells being preferably selected from keratinocytes, melanocytes, Merkel cells, Langerhans cells, fibroblasts, mast cells, macrophages, lymphocytes, platelets, lipocytes and any combination thereof. For this, several technics may be used via biochemical or physical means, including electroporation or microinjection [Nathan D. Donahue, et al. Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine. Advanced Drug Delivery Reviews 143 (2019) 68-96]
In any case, the size of the particles below about 100 pm will ensure relevant (i.e., stable) interaction between the particles of the invention and the biological medium where the particles have been injected. A direct interaction of the particle with the cell is possible, and the particle can even operate from within the cell. The particles having the same size-scale as a cell, they are capable of significantly enhancing smooth interactions both with the biological cells and with the biological medium compared to current implants (typically needles used for electroacupuncture have a much larger diameter than the size of a cell).
(ii) The composition of the particles and/or of the particles ’ surface coating agent
When the composition of the particles’ core presents potential safety issues for the subject (i.e. a potential dissolution process triggering direct release of potentially toxic metal elements in the biological medium, and/or a potential redox phenomenon at the surface of the particle triggering oxidation of proteins or biological moieties or generation of reactive oxygen species (ROS), and/or a potential catalytic property of the particles), a surface coating is preferably applied using a surface coating agent.
This surface coating is preferably an inorganic surface coating limiting, ideally preventing, any potential degradation of the organic surface coating agent (such as bond breaking) upon time, ex-vivo (i.e., upon
storage of the particles prior use) or in vivo (i.e., upon injection of the particles in vivo). Indeed, the surface coating agent should ideally not contain carbon-carbon bonds or any bonds susceptible of being broken ex vivo or in vivo (typically due to oxidation phenomenon). Also, when an organic coating agent is selected, precaution regarding sterilization and storage of the particles are to be taken to prevent potential degradation of the surface coating agent, typically due to oxidation reactions. In any case, the surface coating agent should be selected so that potential residues or moieties typically resulting from oxidation reactions and/or bond breaking of the surface coating agent do not triggered in vivo toxicity.
Also, when a surface coating agent is applied to the particles in a particular aspect of the description, this surface coating agent should not desorb from the particles’ core. Therefore, it is key to consider coating agent able to establish strong bonds/links with the surface of the particles, typically able to establish complexing or covalent bonds. Typical covalent bonds are found between silane-based compounds (i.e., coating agents) and the surface of oxide particles. Other very strong bonds (i.e., bonds considered as exhibiting a strength intermediate between the strength exhibited by covalent bonds and that exhibited by complexing bonds) are found between phosphate-based or phosphonate-based compounds (i.e., coating agents) and the surface of oxide particles, or between thiol-based compounds and the surface of metal particles, quantum dots or semiconductor particles.
In any configuration (i.e., whatever the selection of the core of the particle and/or of the surface coating agent), the particles should be stable (i.e., physically and chemically stable) prior their injection in a subject (unless specified that the particles should degrade in vivo). When the particles are in suspension (i.e., dispersed in solution), typically prior injection, they should form a stable suspension. A suspension is considered as stable in the absence of observed sedimentation of the particles (i.e., the appearance of the suspension is homogeneous) within typically 1 minute, 2 minutes or 3 minutes following manual agitation of the suspension. Also, when the particles are in suspension, the supernatant solution collected by any means and free of particles, should present no or a very low amount of elements constituting the particles and/or constituting the particles’ surface coating (i.e. the detected amount of elements should be in the limit of resolution of the technic selected for quantifying these elements which are well-known by the skilled person in the art such as the ICP-MS (inductively coupled plasma - mass spectrometry) or the ICP-OES (inductively coupled plasma - optical emission spectrometry) technics).
The surface of the particles is typically hydrophilic or hydrophobic. An hydrophilic surface ensures the wettability of the particles in aqueous medium and the possibility to obtain a water suspension. Alternatively, an hydrophobic surface is not wet by water. However, a particle with an hydrophobic surface can be wet by biological entities (such as proteins absorption on the surface of the hydrophobic particles), present in the biological medium. Particles contact angles with water measurement represents a typical wettability measurement to assess particles’ hydrophobicity. In such measurement, particles are dispersed in ultrapure water and left to dry on a substrate to create a homogeneous layer of particles. The contact angle measurement is performed with water as probe liquid, at room temperature. Typical hydrophobic particles have a contact angle with water above about 50°,
preferably above about 60°, 70°, 80° or 90°. Typical hydrophilic particles have a contact angle with water below about 30°, preferably below about 25°, 20° or 10°. Quantification of nanoparticle surface’s hydrophobicity is also proposed by comparing nanomaterial binding affinity to two or more engineered collector [Andrea Valsesia et al. Direct quantification of nanoparticle surface hydrophobicity. Communications Chemistry, 2018, 1:53]
When the particles are hydrophilic and have a size typically below about 20 pm, preferably below about 10 pm, they have typically a surface charge below about +30 mV to avoid any potential in vivo toxicity triggered by the surface charge. In this context, the surface charge is typically measured through the so-called zeta potential of the particles, the particles being in a water solution (i) at pH between about 6.5 and about 7.5, (ii) at a particles’ concentration between 0.5 g/kg and 10 g/kg (weight/weight), the particles concentration being typically measured by dry extract (i.e. the suspension containing the particles is typically placed at a temperature between 100°C and 250°C for a period typically comprised between 15 minutes and overnight) or by ICP-MS or ICP-OES and (iii) at an ionic strength presenting an electrical conductivity typically between about 0.01 pS/cm and about 2000 pS/cm at a temperature between about 15°C and about 25°C.
DISEASES AND RELATED ACUPOINTS OR NA US
In a particular and preferred aspect, inventors herein describe particles for use for treating a subject suffering of a disease, disorder or dysfunctional state as herein described via an acupuncture effect, when particles stably interact with biological cells, free nerve endings, end-organs, nerve fibers and/or sarcous sensory receptors of at least one acupoint or NAU of the subject. As explained herein above, preferred particles have a size below 100 pm and are prepared from a material selected from a piezoelectric material, a pyroelectric material and a far-infrared radiation emitting -material.
The term “Treatment” refers to both therapeutic and prophylactic or preventive treatment or measures able to alleviate or cure a disease, disorder or dysfunctional state. Such a treatment is intended for a mammal subject, preferably a human subject, in need thereof, whatever its age or sex. Are considered as such, the subjects suffering from a disease, disorder or dysfunctional state, or those considered “at risk of developing” such a disease, disorder or dysfunctional state, in which this has to be prevented.
In the context of the present invention, diseases encompasses inflammatory and infection diseases, disorders or dysfunctional state, for example inflammatory bowel disease, appendicitis, peptic ulcer, gastric ulcer, duodenal ulcer, peritonitis, pancreatitis, ulcerative colitis, pseudomembranous colitis, acute colitis, ischemic colitis, diverticulitis, epiglottitis, achalasia, cholangitis, cholecystitis, hepatitis, Crohn's disease, enteritis, Whipple's disease, allergy, anaphylactic shock, immune complex
disease, organ ischemia, reperfusion injury, organ necrosis, hay fever, sepsis, septicemia, endotoxic shock, cachexia, hyperpyrexia, eosinophilic granuloma, granulomatosis, sarcoidosis, septic abortion, epididymitis, vaginitis, prostatitis, urethritis, chronic obstructive pulmonary disease, bronchitis, emphysema, rhinitis, pneumonitis, alveolitis, bronchiolitis, pharyngitis, pleurisy, sinusitis, influenza, respiratory syncytial virus infection, HIV infection, hepatitis B virus infection, hepatitis C virus infection, herpes virus infection disseminated bacteremia, Dengue fever, candidiasis, malaria, filariasis, amebiasis, hydatid cysts, bums, dermatitis, dermatomyositis, sunburn, urticaria, warts, wheals, vasculitis, angiitis, endocarditis, arteritis, atherosclerosis, thrombophlebitis, pericarditis, myocarditis, myocardial ischemia, periarteritis nodosa, rheumatic fever, Alzheimer's disease, coeliac disease, congestive heart failure, adult respiratory distress syndrome, meningitis, encephalitis, multiple sclerosis, cerebral infarction, cerebral embolism, Guillaume-Barre syndrome, neuritis, neuralgia, spinal cord injury, paralysis, uveitis, arthritides, arthralgias, osteomyelitis, fasciitis, Paget's disease, gout, periodontal disease, rheumatoid arthritis, psoriatic arthritis, synovitis, myasthenia gravis, thyroiditis, systemic lupus erythematosus, Goodpasture's syndrome, Behcet’s syndrome, allograft rejection, graft- versus-host disease, Type I diabetes, Type II diabetes, ankylosing spondylitis, Berger's disease, Reiter's syndrome, depression, Hodgkin's disease and cancer.
In a preferred embodiment, treatment is performed in a subject suffering from type 2 diabetes, inflammatory bowel diseases including typically ulcerative colitis and Crohn’s disease, chronic obstructive pulmonary disease, depression, rheumatoid arthritis or psoriatic arthritis.
In a particular aspect, the acupoint or the scalp acupuncture line is selected from LU1, LU2, LU3, LU4, LU5, LU6, LU7, LU8, LU9, LU10, LU11, LI1, LI2, LI3, LI4, LI5, LI6, LI7, LI8, LI9, LI10, LI11, LI 12, LI13, LI14, LI15, LI16, LI17, LI18, LI19, LI20, ST1, ST2, ST3, ST4, ST5, ST6, ST7, ST8, ST9, ST10, ST11, ST12, ST13, ST14, ST15, ST16, ST17, ST18, ST19, ST20, ST21, ST22, ST23, ST24, ST25, ST26, ST27, ST28, ST29, ST30, ST31, ST32, ST33, ST34, ST35, ST36, ST37, ST38, ST39, ST40, ST41, ST42, ST43, ST44, ST45, SP1, SP2, SP3, SP4, SP5, SP6, SP7, SP8, SP9, SP10, SP11, SP12, SP13, SP14, SP15, SP16, SP17, SP18, SP19, SP20, SP21, HT1, HT2, HT3, HT4, HT5, HT6, HT7, HT8, HT9, SI1, SI2, SI3, SI4, SI5, SI6, SI7, SI8, SI9, SI10, Sil l, SI12, SI13, SI14, SI15, SI16, SI 17, SI18, SI 19, BL1, BL2, BL3, BL4, BL5, BL6, BL7, BL8, BL9, BL10, BL11, BL12, BL13, BL14, BL15, BL16, BL17, BL18, BL19, BL20, BL21, BL22, BL23, BL24, BL25, BL26, BL27, BL28, BL29, BL30, BL31, BL32, BL33, BL34, BL35, BL36, BL37, BL38, BL39, BL40, BL41, BL42, BL43, BL44, BL45, BL46, BL47, BL48, BL49, BL50, BL51, BL52, BL53, BL54, BL55, BL56, BL57, BL58, BL59, BL60, BL61, BL62, BL63, BL64, BL65, BL66, BL67, KI1, KI2, KI3, KI4, KI5, KI6, KI7, KI8, KI9, KI10, Kil l, KI12, KI13, KI14, KI15, KI16, KI17, KI18, KI19, KI20, KI21, KI22, KI23, KI24, KI25, KI26, KI27, PCI, PC2, PC3, PC4, PC5, PC6, PC7, PC8, PC9, TE1, TE2, TE3, TE4, TE5, TE6, TE7, TE8, TE9, TE10, TE11, TE12, TE13, TE14, TE15, TE16, TE17, TE18, TE19, TE20, TE21, TE22, TE23, GB1, GB2, GB3, GB4, GB5, GB6, GB7, GB8, GB9, GB10, GB11, GB12, GB13, GB14, GB15,
GB16, GB17, GB18, GB19, GB20, GB21, GB22, GB23, GB24, GB25, GB26, GB27, GB28, GB29, GB30, GB31, GB32, GB33, GB34, GB35, GB36, GB37, GB38, GB39, GB40, GB41, GB42, GB43, GB44, LR1, LR2, LR3, LR4, LR5, LR6, LR7, LR8, LR9, LR10, LR11, LR12, LR13, LR14, GV1, GV2, GV3, GV4, GV5, GV6, GV7, GV8, GV9, GV10, GV11, GV12, GV13, GV14, GV15, GV16, GV17, GV19, GV20, GV21, GV22, GV23, GV24, GV25, GV26, GV27, GV28, CV1, CV2, CV3, CV4, CV5, CV6, CV7, CV8, CV9, CV10, CV11, CV12, CV13, CV14, CV15, CV16, CV17, CV18, CV19, CV20, CV21, CV22, CV23, CV24, EX-HN1, EX-HN2, EX-HN3, EX-HN4, EX-HN5, EX-HN6, EX-HN7, EX-HN8, EX-HN9, EX-HN10, EX-HN11, EX-HN12, EX-HN13, EX-HN14, EX-HN15, EX-CA1, EX- Bl, EX-B2, EX-B3, EX-B4, EX-B5, EX-B6, EX-B7, EX-B8, EX-B9, EX-UE1, EX-UE2, EX-UE3, EX-UE4, EX-UE5, EX-UE6, EX-UE7, EX-UE8, EX-UE9, EX-UE10, EX-UE11, EX-LEI, EX-LE2, EX-LE3, EX-LE4, EX-LE5, EX-LE6, EX-LE7, EX-LE8, EX6LE9, EX-LE10, EX-LE11, EX-LE12, MSI, MS2, MS3, MS4, MS5, MS6, MS7, MS8, MS9, MS10, MS11, MS12, MS13 and MS14.
In another particular aspect, several acupoints or scalp acupuncture lines are activated during a protocol/method as herein described such as at least 2 acupoints or scalp acupuncture lines, for example 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 acupoints or scalp acupuncture lines, said lines being selected from MSI, MS2, MS3, MS4, MS5, MS6, MS7, MS8, MS9, MS10, MS11, MS12, MS13 and MS14.
The following acupoints are preferred (i.e., a preferred acupoint may be selected from): BL10, BL11, BL13, BL14, BL15, BL18, BL20, BL22, BL23, BL36, BL40, BL54, BL56, BL60, BL62, CV4, CV6, CV12, CV17, EX-B1, EX-LE2, EX-LE4, EX-LE5, EX-UE4, EX-UE9, GB12, GB20, GB21, GB25, GB30, GB31, GB33, GB34, GB39, GB40, GV4, GV14, GV20, HT5, HT7, KI3, KI6, KI10, KI13, LI4, LI5, LI11, LI15, LI18, LR3, LU1, LU9, PC6, SI3, SI4, SI9, SI11, SP4, SP6, SP9, SP10, ST5, ST25, ST28, ST34, ST35, ST36, ST37, ST41, TE4, TE5 and TE14.
In the context of rheumatoid arthritis, the following acupoints are preferred (i.e., a preferred acupoint may be selected from): BL11, BL18, BL20, BL23, BL36, BL54, BL56, BL60, BL62, CV4, CV6, CV12, EX-LE2, EX-LE4, EX-LE5, EX-UE4, EX-UE9, GB20, GB25, GB30, GB31, GB33, GB34, GB39, GB40, GV4, GV14, GV20, HT7, KI3, KI6, KI10, KI13, LI4, LI5, LI11, LI15, LR3, PC6, SI3, SI4, SI9, Sill, SP6, SP9, SP10, ST5, ST25, ST34, ST36, ST41, TE4, TE5 and TE14 [Pei-Chi Chou et al. Clinical efficacy of acupuncture on rheumatoid arthritis and associated mechanisms: a systemic review. Evidence-Based Complementary and Alternative Medicine 2018, ID8596918]
In the context of osteoarthritis, the following acupoints are preferred (i.e., a preferred acupoint may be selected from): ST35, EX-LE5, GB34, SP9, GB39 and SP6 [X. Chen et al. The modulation effect of longitudinal acupuncture on resting state functional connectivity in knee osteoarthritis patients. Mol Pain (2015) 11:67]
In the context of inflammatory bowel disease, the following acupoints are preferred (i.e., a preferred acupoint may be selected from): BL18, BL20, BL21, BL23, BL25, CV4, CV12, GV4, GV20, GV26, LI4, LI11, LR3, PC6, SP4, SP9, SP14, SP15, ST21, ST25, ST36, ST37, ST39 and TE5 [Gengqing Song et al. Acupuncture in Inflammatory Bowel Disease. Inflamm. Bowel Dis. 2019, 25(7),
1129-1139] In particular, in the context of Crohn’s disease, the following acupoints are preferred (i.e., a preferred acupoint may be selected from): CV6, CV12, KI13, LI4, LI11, LR3, SP4, SP6, ST25, ST36 and ST37 [Chun-Hui Bao et al. Randomized controlled trial: Moxibustion and acupuncture for the treatment of Crohn’s disease. World J Gastroenterol 2014 August 21; 20(31): 11000-11011]
In the context of diabetes type II, the following acupoints are preferred (i.e., a preferred acupoint may be selected from): BL13, BL14, BL20, BL22, BL23, CV4, CV12, KI13, LI4, LI11, SP6, ST28, ST36 and TE5 [ClinicalTrials.gov Study NCT04076800 ; Acupuncture and Insulin Doses in Insulin- treated Type 2 Diabetes (ACUDIA)] .
In the context of chronic obstructive pulmonary disease (COPD), the following acupoints are preferred (i.e., a preferred acupoint may be selected from): LU1, LU9, LI18, KI3, GB12, BL13, BL20, BL23, CV4, CV12, CV17, EX-B1 and ST36 [Masao Suzuki et al. A Randomized, Placebo-Controlled Trial of Acupuncture in Patients With Chronic Obstructive Pulmonary Disease (COPD). Arch Intern Med. 2012; 172(l l):878-886; Ken SL Lau et al. A single session of Acu-TENS increases FEV1 and reduces dyspnoea in patients with chronic obstructive pulmonary disease: a randomised, placebo-controlled trial. Australian Journal of Physiotherapy 54: 179-184]
In the context of depression, the following acupoints are preferred (i.e., a preferred acupoint maybe selected from): HT7, LI4, ST36, SP6, LR3 andGV20 [ClinicalTrials.gov Study NCT01633996] In a preferred embodiment, particles interact with at least one, preferably several or all, of the following acupoints: BL23, GB34, KI3, LI4, LI11 and ST36.
In another preferred embodiment, the particles interact with at least one and up to ten acupoints, for example 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 acupoints.
The description also relates to a composition for use for treating a subject suffering of a disease, disorder or dysfunctional state as herein described. The composition comprises particles and the therapeutic effect is obtained via an acupuncture effect when the particles stably interact with biological cells, free nerve endings, end-organs, nerve fibers and/or sarcous sensory receptors present (in the biological medium of) at least one acupoint or NAU of the subject. As explained herein above, preferred particles have a size below 100 pm and are prepared from a material selected from a piezoelectric material, a pyroelectric material and a far-infrared emitting -material.
A particular composition comprises between about lmg/lOOg (particles weight/dispersion medium weight) and 40g/100g particles, preferably between about lg/lOOg and lOg/lOOg particles.
Also herein described is the use of such particles for preparing a composition of the invention for treating a subject suffering of a disease as herein described.
The description further relates to a method for delivering acupuncture to a subject in need thereof. When the particles are prepared from a material which is a far-infrared radiation emitting-material, the method typically comprises a step of administering the particles, or a composition comprising the
particles, to at least one acupoint or Neural Acupuncture Unit (NAU) of the subject, thereby triggering an acupuncture effect in the subject.
When the particles are prepared from a piezoelectric material, the method typically comprises a step of administering the particles, or a composition comprising the particles, to at least one acupoint or Neural Acupuncture Unit (NAU) of the subject, and a step of stimulating said particles by a skin massage on the at least one acupoint or NAU, thereby triggering an acupuncture effect in the subject.
When the particles are prepared from a pyroelectric material, the method typically comprises a step of administering the particles, or a composition comprising the particles, to at least one acupoint or Neural Acupuncture Unit (NAU) of the subject, and a step of stimulating said particles by heating the surface of the skin of the subject above the acupoint or NAU, thereby triggering an acupuncture effect in the subject.
The description also relates to a method for treating a subject in need thereof via an acupuncture effect.
When the particles are prepared from a material which is a far-infrared radiation emitting-material, the method typically comprises a step of administering the particles, or a composition comprising the particles, to at least one acupoint or Neural Acupuncture Unit (NAU) of the subject, thereby treating the subject.
When the particles are prepared from a piezoelectric material, the method typically comprises a step of administering the particles, or a composition comprising the particles, to at least one acupoint or Neural Acupuncture Unit (NAU) of the subject, and a step of stimulating said particles by a skin massage on the at least one acupoint or NAU, thereby treating the subject.
When the particles are prepared from a pyroelectric material, the method typically comprises a step of administering the particles, or a composition comprising the particles, to at least one acupoint or Neural Acupuncture Unit (NAU) of the subject, and a step of stimulating particles by heating the surface of the skin of the subject above the acupoint or NAU, thereby treating the subject.
PARTICLES ’ FORMULATION AND ADMINISTRATION
Particles are typically formulated in a liquid or in a gel, in particular in a liquid that turns into a gel when administered on at least one acupoint or NAU of the subject. A particular composition of the invention comprising particles is in the form of a liquid or a gel, in particular in a liquid form that turns into a gel when administered on at least one acupoint or NAU of the subject.
When the transition from a liquid to a gel is triggered by a change of temperature, the liquid-to- gel transition typically occurs between 30°C and 40°C. Poly(D,L-lactic acid-co-glycolic acid)-A poly(ethylene glycol)-ft-poly(D,L-lactic acid-co-glycolic acid) (PUGA-PEG-PUGA) triblock copolymers typically are materials which exhibit a sol-gel transition upon heating. The liquid-to-gel
transition temperature is typically affected by the following parameters: the concentration of copolymer, the chain length of PEG, the chain length of PLGA, the molar ratio between PEG and PLGA, or the lactic acid/glycolic acid (LA:GA) ratio within the PLGA. All these parameters can be easily adjusted by the skilled person to trigger a liquid-to-gel transition at a temperature typically comprised between 30°C and 40°C, for example at the human body temperature.
The herein defined particles are typically part of a composition which is a liquid or a gel, in particular a liquid having a liquid-to-gel transition temperature between 30°C and 40°C.
Thus, a preferred composition for use for treating a subject suffering of disease as herein described is in a liquid or gel form, in particular in the form of a liquid having a liquid-to-gel transition temperature between 30°C and 40°C.
When using a liquid that turns into a gel when administered on at least one acupoint or NAU, a controlled release of the particles at the site of administration can be obtained by an adaptation of the gel according to methods well-known by the skilled person in the art. Depending on the affinity between the particles and the gel, a controlled release of the particles, typically between few seconds (for example about two seconds) and 1 week, can be obtained. Alternatively, according to the kinetic of degradation of the gel, a controlled release of the particles, typically between 1 hour and 1 week, can be obtained.
The affinity between the particles and the gel is typically characterized by the type of bonding existing between the particles and the material constituting the gel. The bonding can typically be an hydrogen bonding, a bonding resulting from electrostatic interactions, a complexing bonding or a chemically cleavable covalent bonding.
The degradation of the gel typically consists in the swelling (i.e., expansion) of the gel or the breaking of bonds in the material(s) constituting the gel. The gel is ideally biodegradable. A biodegradable gel can typically comprises hydrolytic degradable polyesters blocks, such as poly(s- caprolactone) (PCL) blocks and poly(D,L-lactide- co-glycolide) (PLGA), blocks. Alternatively, the biodegradable gel can comprise polymer blocks with enzymatically degradable peptides, such as poly(L- alanine) (PA) blocks and chitosan blocks.
The particles or composition comprising such particles can be directly administered on at least one acupoint or NAU using typically a syringe and a needle when particles are in suspension (i.e., when they are formulated as a liquid or as a gel, provided the viscosity of the gel remains compatible with such administration mode, for example as a liquid that turns into a gel when administered in a subject). When formulated as a gel, the particles can also be deposited on the surface of the skin. Particles will penetrate in the dermis and epidermis for example spontaneously or by massage. In this particular cases, hydrophobic particles are preferred.
Alternatively, the particles can be directly stuck to the surface of a needle and the particles are released in the biological medium typically between few seconds (typically at least two seconds) and 10
minutes following needle insertion into the skin typically up to the dermis and/or the hypodermis layer. Also, the particles can be formulated as a gel which stuck to the surface of a needle, the gel being released in the biological medium typically between few seconds and 10 minutes upon needle insertion in vivo. To stick the particles or the gel containing the particles to the surface of the needle while allowing the rapid release of the particles or of the gel containing the particles from the needle when in vivo, a linker agent containing a chemical cleavable bond or a UV cleavable bond can typically be used. This linker agent binds the particle or the gel containing the particles to the surface of the needle. The linker agent is typically a linker agent containing a chemical cleavable bond such as a cleavable disulphide bond, a cleavable ester bond, or a cleavable hydrazone bond.
The particles can become the principal component of the needle(s), microneedle(s), or of the tip(s) of the needle(s) or microneedle(s). In such case, the needle(s), microneedle(s), or the tip(s) of the needle(s) or microneedle (s) is(are) inserted in vivo and remain(s) there. The erosion (such as degradation or dissolution) of the needle(s), microneedle(s) or of the tip(s) of the needle(s) or microneedle(s) triggers the release of the particles, typically within seconds (for example about 2 seconds), hours, days or weeks following needle(s) or microneedle(s) insertion/ implantation in the skin. The needle(s) or microneedle(s) are left in the skin for a selected period and can be removed at any time extracting the part(s) of the needle(s) or microneedle(s) that has/have not been dissolved. Dissolvable needle(s) or microneedle(s) or dissolvable tip(s) of the needle(s) or microneedle(s) typically comprise(s) water soluble polymers, such as polyvinyl alcohol, polyvinylpyrrolidone or polyvinyl acetate, sugars, or any mixture thereof. The dissolvable needle(s) or microneedle(s) or tip(s) of needle(s) or microneedle(s) comprise(s) the herein described particles.
In a preferred aspect, needle insertion is that observed in the context of acupuncture.
VOLUME AND CONCENTRATION OF PARTICLES AT THE ACUPOINTS
The volume occupied by particles on at least one acupoint or NAU location is typically comprised between about 0.001 mm3 (i.e., 0.001 pL) and about 100 mm3 (i.e., 100 pL), preferentially between about 0.005 mm3, about 0.01 mm3, about 0.05 mm3, about 0.1 mm3, about 0.2 mm3, about 0.5 mm3, about 1 mm3, about 2 mm3, or about 5 mm3, and about 10 mm3, about 20 mm3, or about 50 mm3. The volume occupied by the particle corresponds to the minimum volume measured in vivo (typically using imaging technics well known by the skilled person) which includes all the administered, typically injected, particles. Because the particles remain at their administration site, the volume occupied by the particle corresponds to the administered volume (e.g., the volume of the administered liquid or gel, or the volume of the needle, microneedle or tip of the needle or microneedle which has dissolved). Needle(s) or microneedle(s) which can be used to administer/inject the particles at the acupoint or NAU, have typically the following dimensions: a diameter typically between about 0.10 mm, or more than
about 0.10 mm, and about 0.50 mm or about 0.40 mm, and a length typically between about 1 mm, about 1.5 mm, about 2 mm, or about 5 mm and about 100 mm.
The concentration of particles on at least one acupoint or NAU is typically between 1 mg/lOOg (weight of particles by weight of biological medium) and 40 g / lOOg. Because the particles remain at their administration site, the concentration of particles on at least one acupoint or NAU corresponds to the concentration of particles which is present in the suspension (i.e., the dispersion medium) to be administered in vivo (e.g., the concentration of particles in the liquid or gel, or the concentration of particles in the needle, microneedle or tip of the needle or microneedle).
COMBINATION
The present invention is typically for use for treating a subject suffering of an inflammatory or infection disorder via an acupuncture effect. In a particular aspect, particles can be combined with anti inflammatory agent(s), anti -infectious agent(s) and/or pain relief agent(s).
The anti-inflammatory agent is for example a nonsteroidal anti-inflammatory agent such as diclofenac, ibuprofen or aspirin. The anti-infectious agent is for example an agent from the cephalosporin, penicillin, fluoroquinolone, carbapenem or macrolide class.
The pain relief agent is for example an analgesic agent such as acetaminophen, or an opioid agent such as morphine.
These agents can be administered for example orally, topically, or by local administration, typically by injection, at the site of inflammation. These agents can be administered before, concomitantly or after a treatment method comprising a step of administering the herein described particles, or concomitantly or after particles’ activation/stimulation when a massage or heat treatment step is required by the material the selected particles are made of.
In a particular aspect, the agent(s) and particles are present in the same composition, typically in a composition as herein described, and administered simultaneously to the subject, for example topically. In another particular aspect of the description, particles are combined with an anti-cancer agent such as for example a chemotherapeutic agent or an immunotherapeutic agent, and/or are administered to a subject suffering of a cancer and treated locally by surgery or by radiotherapy. Such a combination may improve the prognosis of cancer patients by promoting anticancer immunity in the patients.
FREQUENCY OF PARTICLES ADMINISTRATION: INVASIVENESS & RISK
The particles can be administered on at least one acupoint or NAU more than once. However, they are preferably designed to be administered only once. In terms of invasiveness and detrimental effects/ risk linked to the administration procedure, a single administration of the particles of the invention is advantageous when compared to repeated needles implantation on at least one acupoint or
NAU, which is typically required in the context of a treatment, especially in the context of chronic disorders.
TREATMENT SESSION FREQUENCY
When the particles are prepared from a piezoelectric material, or when the particles are prepared from a pyroelectric material, the treatment (via activation/stimulation of particles, typically, as taught herein above, by skin massage when particles are prepared from a piezoelectric material and by skin heating when the particles are prepared from a pyroelectric material) can be applied at least once per day, typically two-, three-, for-, five-, six-, seven-, eight-, nine- or ten-times per day, and during at least one day, typically two days, three days, four days, five days, six days, one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, or eight weeks. The treatment can be applied on a regular basis (i.e., every day or every week), or it can be sequenced in periods (typically days or weeks). For instance, the treatment period can last for one month, two months, three months, four months, five months, six month or seven months, where the input energy source is applied once a day, twice a day or three-times a day, 1 day, 2 days, 3 days, 4 days or five days per week.
When a stimulation/activation of the particles is required and performed, the stimulation duration (treatment session duration) is typically between 1 minutes and 60 minutes, preferably between 1 minute and 30 minutes, 1 minute and 15 minutes, 1 minute and 10 minutes, or 1 minute and 5 minutes, for example between 5 seconds, 10 seconds, 15 seconds or 30 seconds and 1 minute, 2 minutes, 3 minutes, 4 minutes or 5 minutes.
Treatment using a heating source to stimulate the particles
When the particles are prepared from a pyroelectric material, a heating step of the surface of the skin of the subject above the acupoint(s) or NAU(s) is performed to stimulate the particles located on said acupoint(s) or NAU(s). Typically, one or several cycle(s) of temperature is/are performed depending on the composition of the particles. The temperature during each cycle typically does not exceed about 40°C in order to avoid skin burning.
In a particular aspect, a cooling step is added to any protocol including a heating step in order to induce a thermic shock which will further enhance the effects of the following heating step applied to the particle, i.e., which will enhance the activation of the cooled particle when reheated.
PATIENT A UTONOMY
When the particles are prepared from a material selected from a piezoelectric material or a pyroelectric material, the number of times per day or per week the treatment should be applied, the frequency of stimulation, its duration, and possibly the intensity of stimulation are typically parameters
that can be delivered to the subject according to a pre-established protocol. As such, the particles used in the context of the present invention facilitate the follow up of the treatment, and are in particular advantageously used in the context of chronic diseases.
The protocol may typically be adjusted upon measuring blood biomarkers (as detailed herein below) when these biomarkers are usable to monitor the disease status in a subject under treatment. The treatment/protocol can then be adjusted/modulated, for example increased or decreased, for example by increasing or reducing the number of times per day or per week the treatment is to be applied, and/or by increasing or reducing the treatment session duration.
BIOMARKERS
In the context of an inflammatory or infection disorder, a panel of serum cytokines can be advantageously measured, typically in the blood. The panel for example comprises IL-6, IL-10, IL- 12p70, IL-13, IL-la, IL-Ib, IL-2, IL-4, IL-8, IL-5, IL-17, IL-23 and/or TNF. Also, HMGB1, C-reactive protein (CRP), vascular endothelial growth factor (VEGF), white blood cell (WBC), platelet, or intercellular adhesion molecule 1 (ICAM-1) can be used each one independently, or in combination, as marker(s) of inflammation. Particularly, IL-6 serum level may be measured in a subject under treatment to assess/monitor the inflammatory or infection disorder evolution. A decreased IL-6 serum level in a patient who responds to therapy is typically correlated with a positive response to treatment of the treated subject.
The embodiments of the invention described above are intended to be merely exemplary, and those skilled in the art will recognize, or will be able to ascertain using no more than routine experimentation, numerous equivalents of herein described specific compounds, materials, particles and compositions as well as equivalents of herein described methods or procedures. All such equivalents are considered to be within the scope of the invention and are encompassed by the appended claims.
LEGENDS TO THE FIGURES
Figure 1: Biological components, i.e., biological cells, free nerve endings, end-organs, nerve fibers and/or sarcous sensory receptors at acupoint or Neural Acupuncture Unit (NAU).
Epidermis (zone I). The epidermis comprises the stratum comeum (nonviable epidermis) layer, the stratum lucidum (viable epidermis) layer, the stratum granulosum (viable epidermis) layer, the stratum spinosum (viable epidermis) layer, and the stratum basal (viable epidermis) layer. The epidermis comprises the following biological cells: the keratinocytes which represent 95% of cells and are present in each layer, and the melanocytes, the Merkel cells, and the Langerhans cells which represent 5% of
the remaining cells and are present in viable epidermis. The epidermis also comprises the following appendages: hairs (hairy skin), sweat glands, sebaceous glands, and lipids.
Dermis (zone ID. The dermis comprises the following biological cells: fibroblasts, mast cells, macrophages, lymphocytes and platelets. The dermis also comprises the following appendages: collagen fibrils, elastic connective tissue, mucopolysaccharides, highly vascularized network, lymph vessels, sensory nerves/nerve fibers, free nerve endings, end-organs such as Pacinian corpuscles, Meissner corpuscles, Ruffini corpuscles and/or longitudinal lanceolate endings, hair follicles, sebaceous gland and sweat glands.
Hvnodermis (zone III). The hypodermis comprises lipocytes. It also comprises the following appendages: loose connective tissue (lipocytes, collagen, elastin fibers), blood vessels, nerves and muscle spindles.
EXPERIMENTAL PART
Particles of the invention
Particles can be manufactured/synthesized according to synthesis methods described in the literature. Characterization of these “as synthesized particles” typically includes the analysis of particles size, composition and structure, the analysis of the composition and surface charge of the particles’ surface, as well as the analysis of the hydrophilic or hydrophobic behavior of the particles.
Typical examples of particles synthesis protocols are described in the following publications:
-N. Lee etal. (Magnetosome-like ferrimagnetic iron oxide nanocubes for highly sensitive MRI of single cells and transplanted pancreatic islets. PNAS, February 15, 2011, vol. 108, no. 7, 2662-2667): Far- infrared radiation emitting particles made of FesCL; and
- A. Merlo et al. (Boron nitride nanomaterials: biocompatibility and bio-applications. Biomater. Sci., 2018, 6, 2298): Piezoelectric particles made of boron nitride (BN).
Treatment protocol
Each test treatment method comprises a step of administering the particles on least one acupoint or NAU of the subject to be treated and, when the particles are prepared from a material selected from a piezoelectric material or a pyroelectric material, a subsequent step comprising the stimulation of the particles by a skin massage or a skin heating respectively. The following groups/conditions are typically tested to assess the efficiency of the treatment:
Control group n° 1 : healthy / no treatment;
Control group n°2: healthy / particles’ injection on at least one acupoint but no activation; Control group n°3: diseased / treatment by acupuncture, typically electroacupuncture, transcutaneous electrical nervous stimulation (TENS), percutaneous electrical nervous stimulation
(PENS), or any other bioelectronic medicine tool known to stimulate peripheral nerves such as the invasive vagus nerve stimulation;
Test Group n°l: diseased / injection of particles prepared from a far-infrared radiation-emitting material on at least one acupoint but no activation; - Test Group n°2: diseased / injection of particles on at least one acupoint and when the particles are prepared from a material selected from a piezoelectric material or a pyroelectric material, a subsequent step comprising the stimulation of the particles by a skin massage or a skin heating respectively. Particles of the invention for use for treatment of an infection
A LPS-induced cytokine release mouse model can typically be used as a mouse model of sepsis to monitor serum biomarkers under different conditions.
Particles of the invention for use for treatment of an inflammatory disorder Mice models of Rheumatoid Arthritis, diabetes, or Inflammatory Bowel Disease can typically be used to monitor biomarkers such as cytokines.
Claims
1. Particles for use for treating a subject suffering of a disease via an acupuncture effect when particles stably interact with biological cells, free nerve endings, end-organs, nerve fibers and/or sarcous sensory receptors present in the biological medium of at least one acupoint or Neural Acupuncture Unit (NAU) of the subject, wherein particles are below 100 pm and are prepared from a material selected from a piezoelectric material, a pyroelectric material and a far-infrared radiation-emitting material.
2. The particles for use of claim 1, wherein the particles are prepared from a piezoelectric material and wherein the particles are for use in a method of treating a subject comprising a skin massage step on the acupoint or NAU.
3. The particles for use of claim 1, wherein the particles are prepared from a pyroelectric material and wherein the particles are for use in a method of treating a subject comprising a step of heating the surface of the skin of the subject above the acupoint or NAU.
4. A composition for use for treating a subject suffering of a disease, wherein the composition comprises particles, the particles are below 100 pm and are prepared from a material selected from a piezoelectric material, a pyroelectric material and a far-infrared-emitting material, and the therapeutic effect is obtained via an acupuncture effect when particles stably interact with biological cells, free nerve endings, end-organs, nerve fibers and/or sarcous sensory receptors present in the biological medium of at least one acupoint or Neural Acupuncture Unit (NAU) of the subject.
5. The composition according to claim 4, wherein the composition is a liquid or a gel, in particular a liquid having a liquid-to-gel transition temperature between 30°C and 40°C.
6. The particles for use of anyone of claims 1-3 or the composition for use of claims 4-5, wherein the acupoint is selected from BL10, BL11, BL13, BL14, BL15, BL18, BL20, BL22, BL23, BL36, BL40, BL54, BL56, BL60, BL62, CV4, CV6, CV12, CV17, EX-B1, EX-LE2, EX-LE4, EX-LE5, EX-UE4, EX-UE9, GB12, GB20, GB21,GB25, GB30, GB31, GB33, GB34, GB39, GB40, GV4, GV14, GV20, HT5, HT7, KI3, KI6, KI10, KI13, LI4, LI5, LI11, LI15, LI18, LR3, LU1, LU9, PC6, SI3, SI4, SI9, Sill, SP4, SP6, SP9, SP10, ST5, ST25, ST28, ST34, ST35, ST36, ST37, ST41, TE4, TE5 and TE14.
7. The particles for use or the composition for use of claim 6, wherein particles interact with 1 to 10 acupoints.
8. The particles for use according to claim 1-3, 6 or 7, or the composition for use according to claim 5-7, wherein the disease is selected from type 2 diabetes, inflammatory bowel disease, chronic obstructive pulmonary disease, depression, rheumatoid arthritis and psoriatic arthritis.
9. The particles for use according to claim 1-3 or 6-8, or the composition for use according to claim 5-8, wherein biological cells are keratinocytes, melanocytes, Merkel cells, Langerhans cells, fibroblasts, mast cells, macrophages, lymphocytes, platelets and/or lipocytes, and the end- organs are Meissner corpuscles, Ruffini corpuscles, Pacinian corpuscles and/or longitudinal lanceolate endings.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20315200.4 | 2020-04-20 | ||
EP20315200 | 2020-04-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021213759A1 true WO2021213759A1 (en) | 2021-10-28 |
Family
ID=70968891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2021/057372 WO2021213759A1 (en) | 2020-04-20 | 2021-03-23 | Particles for therapeutic purposes |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2021213759A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006073484A2 (en) | 2004-12-27 | 2006-07-13 | North Shore-Long Island Jewish Research Institute | Treating inflammatory disorders by electrical vagus nerve stimulation |
US20080063736A1 (en) * | 2004-11-30 | 2008-03-13 | Jin Sub Kim | Composition Having Effect Of Moxibustion And Press Pellet Using The Same |
DE102008023228A1 (en) * | 2008-05-08 | 2009-11-19 | Technische Universität Dresden | Nanoparticle comprising piezoelectric, pyroelectric or ferroelectric crystalline core material with electric dipole properties, useful as an agent for selective tissue therapy |
US20130171200A1 (en) * | 2011-12-30 | 2013-07-04 | Tuming You | Heat Patch for Diabetes |
US20150283265A1 (en) * | 2005-08-05 | 2015-10-08 | Gholam A. Peyman | Methods to regulate polarization and enhance function of cells |
-
2021
- 2021-03-23 WO PCT/EP2021/057372 patent/WO2021213759A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080063736A1 (en) * | 2004-11-30 | 2008-03-13 | Jin Sub Kim | Composition Having Effect Of Moxibustion And Press Pellet Using The Same |
WO2006073484A2 (en) | 2004-12-27 | 2006-07-13 | North Shore-Long Island Jewish Research Institute | Treating inflammatory disorders by electrical vagus nerve stimulation |
US20150283265A1 (en) * | 2005-08-05 | 2015-10-08 | Gholam A. Peyman | Methods to regulate polarization and enhance function of cells |
DE102008023228A1 (en) * | 2008-05-08 | 2009-11-19 | Technische Universität Dresden | Nanoparticle comprising piezoelectric, pyroelectric or ferroelectric crystalline core material with electric dipole properties, useful as an agent for selective tissue therapy |
US20130171200A1 (en) * | 2011-12-30 | 2013-07-04 | Tuming You | Heat Patch for Diabetes |
Non-Patent Citations (27)
Title |
---|
A. MERLO ET AL.: "Boron nitride nanomaterials: biocompatibility and bio-applications", BIOMATER. SCI., vol. 6, 2018, pages 2298 |
ANDREA VALSESIA ET AL.: "Direct quantification of nanoparticle surface hydrophobicity", COMMUNICATIONS CHEMISTRY, vol. 1, 2018, pages 53 |
B. MERCANTE ET AL.: "Auricular Neuromodulation: the Emerging Concept beyond the Stimulation of Vagus and Trigeminal nerves", MEDICINES, vol. 10, 2018, pages 3 - 12 |
CHUN-HUI BAO ET AL.: "Randomized controlled trial: Moxibustion and acupuncture for the treatment of Crohn's disease", WORLD J GASTROENTEROL, vol. 20, no. 31, 21 August 2014 (2014-08-21), pages 11000 - 11011 |
D. FOX: "The electric Cure", NATURE, vol. 545, 2017, pages 20 - 22 |
DO-HEE KIM ET AL.: "Acupuncture points can be identified as cutaneous neurogenic inflammatory spots", SCIENTIFIC REPORT, vol. 7, 2017, pages 15214 |
GENGQING SONG ET AL.: "Acupuncture in Inflammatory Bowel Disease", INFLAMM. BOWEL DIS., vol. 25, no. 7, 2019, pages 1129 - 1139 |
H.-D. LIM ET AL.: "Anti-inflammatory effects of acupuncture stimulation via the vagus nerve", PLOS ONE, 2016 |
J.M. HUSTON ET AL.: "The inflammatory reflex and neural tourniquet: harnessing the healing power of the vagus nerve", BIOELECTRON. MED., vol. 1, no. 1, 2018, pages 29 - 38 |
JAICY JACOB ET AL: "Piezoelectric smart biomaterials for bone and cartilage tissue engineering", ENSHOU, SAISEI - INFLAMMATION AND REGENERATION, vol. 38, no. 1, 27 December 2018 (2018-12-27), JP, XP055634014, ISSN: 1880-9693, DOI: 10.1186/s41232-018-0059-8 * |
K.J. TRACEY, REFLEXES IN IMMUNITY. CELL, vol. 164, 28 January 2016 (2016-01-28), pages 343 |
K.J. TRACEY: "The Inflammatory Reflex", NATURE, vol. 420, 2002, pages 853 - 859 |
KEN SL LAU ET AL.: "A single session of Acu-TENS increases FEV1 and reduces dyspnoea in patients with chronic obstructive pulmonary disease: a randomised, placebo-controlled trial", AUSTRALIAN JOURNAL OF PHYSIOTHERAPY, vol. 54, pages 179 - 184 |
KEVIN J. TRACEY: "The inflammatory reflex", NATURE, vol. 420, 2002, pages 853 - 859 |
L. ULLOA ET AL.: "Nerve Stimulation: Immunomodulation and Control of Inflammation", TRENDS MOL. MED, vol. 23, no. 12, 2017, pages 1103 - 1120, XP085289192, DOI: 10.1016/j.molmed.2017.10.006 |
L. ULLOA ET AL.: "Nerve Stimulation: Immunomodulation and Control of Inflammation", TRENDS MOL. MED., vol. 23, no. 12, 2017, pages 1103 - 1120, XP085289192, DOI: 10.1016/j.molmed.2017.10.006 |
MASAO SUZUKI ET AL.: "A Randomized, Placebo-Controlled Trial of Acupuncture in Patients With Chronic Obstructive Pulmonary Disease (COPD", ARCH INTERN MED., vol. 172, no. 11, 2012, pages 878 - 886 |
MENNA R. CLATWORTHY ET AL., THE NERVOUS SPLEEN. IMMUNOLOGY AND CELL BIOLOGY, vol. 86, 2008, pages 1 - 2 |
N. LEE ET AL.: "Magnetosome-like ferrimagnetic iron oxide nanocubes for highly sensitive MRI of single cells and transplanted pancreatic islets", PNAS, vol. 108, no. 7, 15 February 2011 (2011-02-15), pages 2662 - 2667, XP055157611, DOI: 10.1073/pnas.1016409108 |
NATHAN D. DONAHUE ET AL.: "Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine", ADVANCED DRUG DELIVERY REVIEWS, vol. 143, 2019, pages 68 - 96, XP085812350, DOI: 10.1016/j.addr.2019.04.008 |
R. TORRES-ROSAS ET AL.: "Dopamine mediates vagal modulation of the immune system by electroacupuncture", NATURE MEDICINE, vol. 20, 2014, pages 291 - 295 |
S. S. CHAVAN ET AL.: "Regulating innate immunity with dopamine and electroacupuncture", NATURE MEDICINE, vol. 20, no. 3, 2014, pages 239 - 241 |
SANGEETA S. CHAVAN ET AL.: "Essential Neuroscience in Immunology", THE JOURNAL OF IMMUNOLOGY, vol. 198, 2017, pages 3389 - 3397 |
VALENTIN A. PAVLOV ET AL.: "Neural regulation of immunity: molecular mechanisms and clinical translation", NATURE NEUROSCIENCE, vol. 20, no. 2, 2017, pages 156 - 166 |
X. CHEN ET AL.: "The modulation effect of longitudinal acupuncture on resting state functional connectivity in knee osteoarthritis patients", MOL PAIN, vol. 11, 2015, pages 67 |
YA YANG ET AL: "Pyroelectric Nanogenerators for Harvesting Thermoelectric Energy", NANO LETTERS, vol. 12, no. 6, 2 May 2012 (2012-05-02), US, pages 2833 - 2838, XP055740563, ISSN: 1530-6984, DOI: 10.1021/nl3003039 * |
YU FAN ET AL.: "Enhanced spinal neuronal responses as a mechanism for increased number and size of active acupoints in visceral hyperalgesia", SCIENTIFIC REPORT, vol. 10, 2020, pages 10312 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zheng et al. | Multimodal treatment for spinal cord injury: a sword of neuroregeneration upon neuromodulation | |
US8600494B2 (en) | Method and device for treating abnormal tissue growth with electrical therapy | |
CN105209014B (en) | Pharmaceutical composition and its application containing botulic neurotoxin | |
JP2004508847A (en) | Method and apparatus for stimulating the pterygopalatine ganglion to improve blood-brain barrier and cerebral blood flow properties | |
Lee et al. | Substance P and beta endorphin mediate electroacupuncture induced analgesic activity in mouse cancer pain model | |
US20050222646A1 (en) | Method and device for treating cancer with modified output electrical therapy | |
KR20190105592A (en) | Nanoparticles for use in the treatment of neuronal disorders | |
KR20190067219A (en) | Use of neurotoxic injury-related polypeptides in pain prevention, relief or treatment | |
JPS59501265A (en) | Method for producing an antispasmodic preparation, especially for muscle spasms, which is fixed on the skin | |
Tynan et al. | Control of inflammation using non-invasive neuromodulation: past, present and promise | |
Xiong et al. | Pulse width modulation electro-acupuncture on cardiovascular remodeling and plasma nitric oxide in spontaneously hypertensive rats | |
US20180345030A1 (en) | Ionized gas for medical treatment | |
WO2021213759A1 (en) | Particles for therapeutic purposes | |
WO2021213767A1 (en) | System comprising particles and a removable device for therapeutic purposes | |
WO2021213756A1 (en) | System comprising genetically modified cells and/or modified nerve fibers and a removable device for therapeutic purposes | |
Zhang et al. | Wireless-Powering Deep Brain Stimulation Platform Based on 1D-Structured Magnetoelectric Nanochains Applied in Antiepilepsy Treatment | |
CN102166302A (en) | Metabolism-compensation method for treating rheumatic osteoarthritis and proportioning and preparing process of preparation thereof | |
CN103330898B (en) | Traditional Chinese medicine composition for curing impotence and prospermia, as well as preparation method and application of traditional Chinese medicine composition | |
Escobar-Chávez | Physical Penetration Enhancers: Therapeutic Applications and Devices | |
Rodríguez-Cruz et al. | Physical penetration enhancers: an overview | |
Song et al. | Neuromodulation of the peripheral nervous system: Bioelectronic technology and prospective developments | |
US20200397710A1 (en) | Magnetoelectric nanoparticles for acupuncture treatment of diseases | |
Luo et al. | Self‐Powered Electrically Controlled Drug Release Systems Based on Nanogenerator | |
CN211097050U (en) | Device for treating tumor by adopting electromagnetic field | |
Shimoji et al. | Other Methods: Minimally Invasive Techniques in Pain Clinic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21713030 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21713030 Country of ref document: EP Kind code of ref document: A1 |